GPR75 antagonists and methods and uses for treating metabolic diseases
GPR75 antagonists address the inadequacies in treating obesity and related metabolic disorders by modulating intestinal lipid metabolism and gut health, demonstrating efficacy in reducing fat absorption and improving metabolic parameters.
Patent Information
- Application Number
- PCT/SG2026/050281
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-05
- Filing Date
- 2026-05-04
- Publication Date
- 2026-11-12
AI Technical Summary
Current therapeutic strategies are inadequate for addressing obesity and associated metabolic disorders, such as type 2 diabetes, cardiovascular disease, and metabolic dysfunction-associated steatotic liver disease, due to the incomplete understanding of the role of GPR75 in regulating whole-body energy homeostasis.
Development of GPR75 antagonists, specifically compounds that inhibit GPR75 activity with high potency and selectivity, to modulate intestinal lipid metabolism and gut health, thereby treating metabolic diseases.
The GPR75 antagonists effectively reduce intestinal fat absorption, enhance fecal lipid excretion, improve gut barrier integrity, and modulate gut microbiome composition, leading to improved metabolic parameters and reduced weight gain in animal models.
Smart Images

Figure IMGF000001_0001 
Figure IMGF000002_0001 
Figure IMGF000002_0002
Abstract
Description
GPR75 ANTAGONISTS AND METHODS AND USES FOR TREATING METABOLIC DISEASESTECHNOLOGICAL FIELD
[0001] The present disclosure relates generally to the fields of pharmacology, biochemistry, and metabolic disease therapeutics. More specifically, the disclosure relates to compounds that act as antagonists of G protein-coupled receptor 75 (GPR75), pharmaceutical compositions comprising such compounds, and methods of using such compounds for the treatment of metabolic diseases. The disclosure further relates to methods of modulating intestinal lipid metabolism and gut health through GPR75 antagonism.BACKGROUND
[0002] Obesity, characterized by excessive fat accumulation, is a major global public health issue, affecting approximately 15% of the world’s population1. As a significant risk factor for chronic diseases such as type 2 diabetes (T2D), cardiovascular disease (CVD), metabolic dysfunction-associated steatotic liver disease (MASLD), and cancer, among others, there is an urgent need for innovative therapeutic strategies to combat the rising prevalence of obesity across the world.
[0003] GPR75 is an orphan G protein-coupled receptor that belongs to Class A (Rhodopsin) family. Large-scale human exome sequencing studies have uncovered that individuals carrying GPR75 loss of function (LOF) variants are protected against obesity2131 4. In line with human genetic findings, global depletion of GPR75 in mice protects against diet-induced obesity and associated metabolic syndromes, including insulin resistance and MASLD2 4'5'6'7'8. However, despite this strong genetic and physiological evidence, the precise tissues and mechanisms through which GPR75 regulates whole-body energy homeostasis remain incompletely understood.
[0004] Therefore, there is a need to further understand the role of GPR75, especially in the regulation of whole-body energy homeostasis, and there is a need to understand whether GPR75 agonism or antagonism may be useful in regulating whole-body energy homeostasis and for treating metabolic diseases or syndromes.SUMMARY OF THE INVENTION
[0005] The following summary is provided to introduce a selection of concepts in a simplified form that are further described below in the Detailed Description. This summary is not intended to identify essential elements or limit the scope of the claimed subject matter.
[0006] In one embodiment, there is provided herein a compound of formula I, formula II, formula III or formula IV, ora pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof:formula (IV);wherein:X, Y, Z, and Q are independently C, S, O, or N;R1is a 3-6 membered monocyclic ring;R2is H or a halogen; andR3, R4, R5, and R6are independently H or Ci-C6alkyl, optionally the Ci-C6alkyl is substituted with one or more halogens.
[0007] In another embodiment of the above compound, the compound is an antagonist of the G protein-coupled receptor 75 (GPR75).
[0008] In yet another embodiment of the above compound or compounds, the compound exhibits an IC50 of less than 10 μM, 5 μM, 2 μM, or 1 μM for inhibition of GPR75.
[0009] In yet another embodiment of the above compound or compounds, the compound selectively inhibits GPR75, preferably with at least 2-fold, at least 5-fold, at least 10-fold, at least 20-fold, at least 50-fold, or at least 100-fold greater potency for GPR75 relative to G protein-coupled receptor 146 (GPR 146).
[0010] In another embodiment, there is provided herein a method of treating a metabolic disease in a subject, the method comprising administering a therapeutically effective amount of a compound of formula I, formula II, formula III or formula IV, ora pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, to the subject in need thereof:(IV); wherein:X, Y, Z, and Q are independently C, S, O, or N;R1is a 3-6 membered monocyclic ring;R2is H or a halogen; andR3, R4, R5, and R6are independently H or Ci-C6alkyl, optionally the Ci-C6alkyl is substituted with one or more halogens.
[0011] In another embodiment of the above method, the metabolic disease is a G protein-coupled receptor 75 associated metabolic disease.
[0012] In yet another embodiment of the above method or methods, the metabolic disease is obesity, Type 2 Diabetes (T2D), cardiovascular disease (CVD), Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) / Non-Alcoholic Fatty Liver Disease (NAFLD), or insulin resistance or a combination thereof.
[0013] In another embodiment, there is provided herein a method of reducing intestinal fat absorption, increasing fecal lipid excretion, modulating gut microbiome composition, reducing intestinal permeability, improving gut barrier integrity and / or reducing chylomicron secretion in a subject, the method comprises administering a therapeutically effective amount of a compound of formula I, formula II, formula III or formula IV, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, to the subject in need thereof:formula (IV);wherein:X, Y, Z, and Q are independently C, S, O, or N;R1is a 3-6 membered monocyclic ring;R2is H or a halogen; andR3, R4, R5, and R6are independently H or Ci-C6alkyl, optionally the Ci-C6alkyl is substituted with one or more halogens.
[0014] In another embodiment of the above method, the compound inhibits or reduces the activity of G protein-coupled receptor 75.
[0015] In yet another embodiment of the above compound(s) or method(s), in the compound of formula I, formula III or formula IV, X and Y are both N or both S.
[0016] In yet another embodiment of the above compound(s) or method(s), in the compound of formula II, formula III or formula IV, Z and Q are both N.
[0017] In yet another embodiment of the above compound(s) or method(s), in the compound of formula I, R1is a C3-C6cycloalkyl.
[0018] In yet another embodiment of the above compound(s) or method(s), in the compound of formula I, formula III or formula IV, R2is Cl or F.
[0019] In yet another embodiment of the above compound(s) or method(s), in the compound of formula II or formula III, R3is a Ci or C2alkyl.
[0020] In yet another embodiment of the above compound(s) or method(s), in the compound of formula II or formula IV, R4and R5are both methyl groups, preferably, in the compound of formula II, R4and R5are both methyl groups further substituted with one or more halogens, more preferably, in the compound of formula II, R4and R5are both methyl groups further substituted with two F.
[0021] In yet another embodiment of the above compound(s) or method(s), in the compound of formula IV, both R3and R6are ethyl groups.
[0022] In yet another embodiment of the above compound(s) or method(s), the compound of formula I, formula II, formula III or formula IV is:or a pharmaceutically acceptable salt, solvate, hydrate, or stereoisomer thereof.
[0023] In another embodiment, there is provided herein a compound as described herein is for use in treating a metabolic disease in a subject in need thereof.
[0024] In another embodiment, there is provided herein a compound as described herein is for use in reducing intestinal fat absorption, increasing fecal lipid excretion, modulating gut microbiome composition, reducing intestinal permeability, improving gut barrier integrity and / or reducing chylomicron secretion in a subject.
[0025] In another embodiment, there is provided herein a method of treating a metabolic disease in a subject, the method comprising administering a therapeutically effective amount of:or a pharmaceutically acceptable salt, solvate, hydrate, or stereoisomer thereof, to the subject in need thereof.BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Other and further aspects and advantages of the present invention will be better understood upon the reading of the illustrative embodiments about to be described, and various advantages not referred to herein will occur to one skilled in the art upon employment of the invention in practice. Having thus generally described the nature of the invention, reference will now be made to the accompanying drawings, showing by way of illustration, embodiments thereof, and in which:
[0027] Figure 1: Generation and Characterization of Gpr75 null mouse model. (A) Schematic diagram showing the generation of Gpr75 whole-body knockout (Gpr75- / -) using CRISPR / Cas9 system. (B) Sanger sequencing showing CRISPR-induced deletion of exon containing Gpr75 coding region. (C) Expression of Gpr75 mRNA in mouse tissues by real-time qPCR. Body weight curve of Gpr75- / -and Gpr75+ / +(D) male mice (n=12-14 mice per group) and (E) female mice fed normal chow diet (n=9-10 mice per group). Quantification of liver and adipose tissues’ weight from Gpr75+ / +and Gpr75+ / +(F) male mice and (G) female mice fed normal chow diet. (H) Fasting plasma TG and (I) TC levels of male Gpr75- / -and Gpr75* mice at different timepoints of HFD feeding. (J) Fasting plasma TG, (K) TC and (L) FFA levels of female Gpr75- / -and Gpr75+ / +mice fed HFD for 18 weeks. Fasting plasma glucose levels from Gpr75' and Gpr75 '!(M) male mice and (N) female mice fed on normal chow and HFD. Data are presented
[0028] Figure 2. GPR75 promotes obesity and related metabolic syndromes. (A) Body weight curve of male Gpr75- / -and Gpr75+ / +mice fed HFD for 16 weeks (n=8 mice per group). Data represented as mean + SEM. (B) Representative images and (C) weight of Liver, eWAT, ingWAT and iBAT from male Gpr75- / -and Gpr75+ / +mice fed HFD for 16 weeks. (D) Body weightcurve of female Gpr75'~ and Gpr75v+mice fed HFD for 18 weeks (n=9 mice per group). Data represented as mean + SEM. (E) Representative images and (F) weight of Liver, eWAT, ingWAT and iBAT from female Gpr7 '' and Gpr75+ / +mice fed HFD for 18 weeks. (G) Representative H&E staining of eWAT, ingWAT, and iBAT from male Gpr75- / -and Gpr75+ / +littermates on HFD for 16 weeks. Scale bar, 100 pm for eWAT and ingWAT, and 50pm for BAT. (H) Quantification of adipocyte size in eWAT and ingWAT. AdipoSoft software is used to quantify 4 regions with an average of 80-100 adipocytes per region. (I) Fasting plasma TG, (J) fasting plasma TC and (K) fasting plasma FFA measurement in male Gpr75- / -and Gpr75i,imice fed normal chow and HFD. (L) Representative H&E staining of liver from male Gpr75 ' and Gpr75+ / +control littermates on HFD for 16 weeks. Scale bar, 50pm. (M) Hepatic TG and (N) hepatic TC levels of male and female Gpr75- / -and Gpr75+ / +control littermates on HFD for 16 weeks and 18 weeks respectively. (O) Plasma ALT activity from male and female Gpr75- / -and Gpr75+ / +mice fed on HFD for 16 weeks and 18 weeks respectively. Data are presented as mean + SD, unless otherwise stated. *P < 0.05, **P < 0.01. All p values were calculated by unpaired two-tailed student’s t tests.
[0029] Figure 3 Gpr75 knockout mice display unchanged food intake, reduced energy expenditure, and an increased respiratory exchange rate. (A) Diagrammatic representation of indirect calorimetry (n=8 male mice per group). (B-E) Food intake in Gpr75- / -and Gpr75tmice fed on CD (left) and HFD (right). (F-l) Energy expenditure in Gpr75- / -and Gpr75+ / +mice fed on CD (left) and HFD (right). (J-M) Respiratory exchange rate (RER) in Gpr75' / _and Gpr75v+mice fed on CD (left) and HFD (right). Graph and analysis were generated by CalR, a web application for indirect calorimetry analysis (https: / / calrapp.org / )- *P 0.05, **P < 0.01.
[0030] Figure 4: Depletion of GPR75 increases water intake and reduces VO2 and VCO2. (A) Body temperature of HFD-fed male Gpr75~'' and Gpr75+ / +mice after overnight (14- 16h) fasting. (B-E) 02 consumption in Gpr75- / -and Gpr75+ / * mice fed CD (left) and HFD (right). (F-l) CO2 production in Gpr75 and Gpr75+ / tmice fed CD (left) and HFD (right). (J-M) Ambulatory activity in Gpr75- / -and Gpr75+ / +mice fed CD (left) and HFD (right). (N-Q) Locomotor activity in Gpr75- / -and Gpr75+ / * mice fed CD (left) and HFD (right). (R-U) Water consumption in Gpr75- / -and Gpr75+ / +mice fed CD (left) and HFD (right). Data in (A) is presented as mean + SD with p value
[0031] Figure 5: GPR75 depletion attenuates intestinal fat absorption and enhances fecal lipid excretion. (A) Schematic of oral gavage with 200µl olive oil with or without 30µg C1-BODIPY 500 / 510 C12 (fluorescent fatty acid analog; Life Technologies #D3823). Blood collected via tail vein before gavage (TO), 60min (T60) and 120min (T120) after gavage. (B) Plasma TG levels after olive oil gavage in Gpr75- / -and Gpr75+ / +mice fed HFD for 8 weeks (n=8 mice per group). Data represented as mean + SEM. (C) Change in Plasma BODIPY (A plasma BODIPY) 2h after olive oil oral gavage in Gpr75- / -and Gpr75+ / +mice fed HFD (n=6 mice per group). (D) Western blotting analyses of Plasma APOB48 and APOB100 of Gpr75- / -and Gpr75+ / +mice fed HFD (n=6 mice per group). (E) Relative quantification of plasma APOB48 and (F) plasma APOB100 by ImageJ of Gpr75- / -and Gpr75+ / +mice fed HFD. (G) Daily weight and (H) representative images of feces collected from Gpr75- / -and Gpr75*7* mice fed HFD for 4 weeks (n=8 mice per group). (I) Number of fecal pellets of Gpr75- / -and Gpr75+ / +mice fed HFD for 4 weeks. (J) Total fecal TG, (K) TC, and (L) FFA levels from Gpr75' and Gpr75+ / +mice fed HFD for 4 weeks. (M) Total fecal protein level from Gpr75+ / +and Gpr75* mice fed HFD for 4 weeks. (N) Representative images and (O) quantification of small intestine (SI) length and (P) colon length from Gpr75- / -and Gpr75+ / * mice fed HFD for 4 and 8 weeks. Data are presented as mean
[0032] Figure 6: GPR75 deficiency attenuates intestinal fat absorption and enhances fecal lipid excretion. (A) Plasma TG and (B) BODIPY levels after olive oil gavage in 7 weeks old Gpr75- / -and Gpr75+ / * mice fed normal chow (n=5 mice per group). Data represented as mean + SEM. (C) Plasma TG and (D) BODIPY levels after olive oil gavage in 12 weeks old Gpr75- / -and Gpr75+ / +mice fed normal chow (n=5 mice per group). Data represented as mean + SEM. (E) Plasma TG area under the curve (AUC) of panel C. (F) Plasma TG levels after olive oil gavage in Gpr75- / -and Gpr75+ / +mice fed HFD for 4 weeks (n=6 mice per group). (G) Post-heparin LPL activity measurement in Gpr75- / -and Gpr75v+mice fed HFD (n=8 mice per group). (H) Weight of feces after drying overnight at 37°C. (I) Width and length of fecal pellets from Gpr75- / -and Gpr75+ / +mice fed HFD for 4 weeks (n=6 mice per group, 30 fecal pellets were measured per mice). A digital vernier caliper was used for the measurement. (J) Relative fecal TG, (K) TC, and (L) FFA levels per gram of feces (mg / g feces) in Gpr75- / -and Gpr75+ / +mice fed HFD for 4 weeks.(M) Fecal TG to FFA ratio of Gpr75- / -and Gpr75* / +mice fed HFD for 4 weeks. (N) Relative fecal protein level per gram of feces (mg / g feces) in Gpr75fand Gpr75+ / +mice fed HFD for 4 weeks.(O) Whole gut transit time in Gpr75- / -and Gpr75+ / +mice fed HFD for 4 weeks (n=9 mice per group).Whole gut transit time is calculated as the time interval between the gavage and the first observed red fecal pellet. (P) Representative image of lacteal LYVE1 staining (red) and (Q) quantification of lacteal length in Gpr75- / -and Gpr75+ / +mice fed HFD for 8 weeks. (R) Representative images of H&E staining (top) and Alcian blue staining (bottom) of Gpr75~ / ~ and Gpr75+ / +mice fed HFD for 8 weeks (n=5 mice per group). Quantification of (S) villi length, (T) crypt depth, (U) mean goblet cell count per villi and (V) mean goblet cell count per crypt in Gpr75'f~ and Gpr75+ / +mice fed HFD for 8 weeks. Data are presented as mean + SD, unless otherwise stated. *P < 0.05, **P < 0.01. AH p values were calculated by unpaired two-tailed student’s t tests.
[0033] Figure 7: Single-cell RNA-Seq and histochemical profiling of GPR75 expression in the intestine. (A) The percentage of GPR75-positive cells across four healthy human donors in different locations of intestinal tract. GPR75 expression in epithelial, stromal, and immune compartments of the human (B) small intestine and (C) human colon. (D) Violin plot showing GPR75 expression among cell types within the epithelial, stromal, and immune compartments of the human small intestine. (E) Expression of Gpr75, as detected by RNAScope (red), in jejunum of the small intestine. Scale bar, 100µm. (F) Volcano plot depicting differentially expressed genes in the jejunum from Gpr75- / -mice and Gpr75* / +mice. Red dots represent genes upregulated in Gpr75+ / +mice while blue dots represent downregulated genes. (G) Gene sets significantly enriched (FDR < 0.25) in the comparison of jejunum from Gpr75- / -mice and Gpr75*7* mice using the gene ontology (GO) annotation, ordered by the increasing NES.
[0034] Figure 8: Single-cell RNA-Seq and histochemical profiling of GPR75 expression in the intestine. (A) Violin plot depicting GPR75 expression among cell types within the epithelial, stromal, and immune compartments of the human colon. Gene sets significantly enriched (FDR < 0.25) in the comparison of jejunum from Gpr75- / -and Gpr75+ / +mice using (B) KEGG and (C) Reactome annotation, ordered by the increasing NES. Chord plot of the (D) top Gene Ontology (GO) terms and (E) KEGG pathways showing a detailed relationship between differentially expressed genes (left semicircle) and their enriched pathways (right semicircle), the Iog2 fold change of individual genes was labelled based on the red-blue color gradient. (F) Intestinal permeability in Gpr75'Aand Gpr75+ / +mice fed HFD for 8 weeks (n=12 mice per group). Data in (F) is presented as mean + SD with p value calculated by unpaired two-tailed student’s t tests. *P < 0.05, **P < 0.01.
[0035] Figure 9: GPR75-deficient mice exhibit a significant change in microbiome composition. (A) Relative abundance at phylum level. (B) Relative abundance of Actinobacteria,Bacteroidetes and Firmicutes. (C) Relative abundance at genus level. Data are presented as
[0036] Figure 10: Alpha and beta diversity plots to visualize the difference in microbiota structure between Gpr75 / ' and Gpr75*'* group. Comparison of alpha diversity of microbiota using (A) Shannon index, (B) Simpson index, (C) Observed, and (D) Fisher (n=8 mice per group). Beta diversity analysis of microbiota using (E) PCoA (principal coordinates analysis (PCoA) plot based on Bray adonis, (F) PCoA plot based on Unifrac adonis metric, (G) NMDS (non-metric multidimensional scaling) clustering analysis based on Bray adonis, and (H) NMDS clustering analysis based on Unifrac adonis metric.
[0037] Figure 11: Deletion of Gpr75 in AgRP neuron, but not enterocytes, reduces body weight gain. (A) Intestinal Gpr75 mRNA expression measured by real-time PCR. (B) Body weight curve of male Gpr75" and W / 7-cre+ / ‘, Gpr75flfmice fed HFD for 7 weeks, (n = 8 mice per group). (C) Liver weights of male Gpr75f / fand Vil1-cre+f', Gpr75" mice fed HFD for 7 weeks, (n = 8 mice per group). (D) Body weight curve of female Gpr75'‘ and Wl-cre7', Gpr75+ / +mice (n = 5 mice per group) fed HFD for21 weeks. (E) Weights of Liver, eWAT, ingWAT and iBAT from female Gpr75mard Vil1-cre+l', Gpr75+ / +mice (n = 5 mice per group) fed HFD for 21 weeks. (F) Expression of Gpr75 mRNA in hypothalamus by real-time qPCR. (G) Body weight curve of male Gpr75" and Agrp-cre+l', Gpr75‘ mice fed HFD for 10 weeks, (n = 7-8 mice per group). (H) Body weight curve of female Gpr75f / fand Agrp-cre+ / ', Gpr75'rmice (n = 6 mice per group) fed HFD for21 weeks. Data
[0038] Figure 12: Deletion of Gpr75 in endothelial cells does not affect body weight gain. (A) Expression of Gpr75 mRNA in artery by real-time qPCR. (B) Body weight curve of male Gpr75flfand Tie2-cre+l', Gpr75+ / +mice fed HFD for 10 weeks, (n = 8-10 mice per group). (C) Liver weight of male Gpr75" and 77e2-cre+ / _, Gpr75f / fmice fed HFD for 10 weeks, (n = 8-10 mice per group). (D) Body weight curve of female Gpr75flfand Tie2-cre+l', Gpr75f,fmice (n = 9 mice per group) fed HFD for 10 weeks. (E) Liver weight of female Gpr75‘" and 77e2-cre+ / _, Gpr75‘ mice (n = 9 mice per group) fed HFD for 10 weeks. Data is presented as mean + SD with p value calculated by unpaired two-tailed student’s t tests. *P < 0.05, **P< 0.01.
[0039] Figure 13: Hepatocyte-specific deletion of Gpr75 does not affect body weight gain or hepatic TG content. (A) Hepatic Gpr75 mRNA expression measured by real-time qPCR.(B) Body weight curve of female Gpr75r / fand Alb-cre+ / -, Gpr75f / fmice (n = 8 mice per group) fed HFD for 10 weeks. (C) Weight of Liver, eWAT, ingWAT and iBAT from female Gpr75f / fand Alb-cre+ / -, Gpr75f / f(n = 8 mice per group) fed HFD for 10 weeks. (D) Body weight curve of male Gpr75f'fand Alb-cre+ / -, Gpr75f / fmice fed HFD for 10 weeks (n=3-7 mice per group). (E) Weight of Liver, eWAT, ingWAT and iBAT from male Gpr75f / fand Alb-cre+ / -, Gpr75f / fmice fed HFD for 10 weeks (n=3-7 mice per group). (F) Quantification of TG content in livers of male or female Gpr75f / fand Alb-cre+ / -, Gpr75f / fmice fed HFD for 10 weeks. calculated by unpaired two-tailed student’s t tests.
[0040] Figure 14. Schematic diagram showing the crude ligand solution preparation pipeline.
[0041] Figure 15. Discovery of ANTAG75-1,2,3,4 as novel antagonists of GPR75. (A) Structure of ANTAG75-1, ANTAG75-2, ANTAG75-3, ANTAG75-4. (B) Dose effect and IC50 of ANTAG75-1,2,3,4 on inhibiting GPR75 activity through p-arrestin recruitment assay. (C) Inhibitory effects of ANTAG75-1,2,3,4 on GPR75 and GPR146 activities through [3-arrestin recruitment assay.
[0042] Figure 16. Pharmacological inhibition of GPR75 reduces diet-induced weight gain and improves metabolic parameters in mice. (A) Experimental design. Male C57BL / 6J mice (7 weeks old, n=10 / group) were fed a high-fat diet (HFD). After 10 days of HFD, mice received vehicle or ANTAG75-4 (Ant-1; 5 mg / kg, i.p.) initially every other day for 2 weeks, followed by dosing every three days during continued HFD feeding. (B) Time course of cumulative body weight gain. (C) Total cumulative weight gain at endpoint. (D-F) Tissue weights at endpoint: liver (D), epididymal white adipose tissue (eWAT, E), and inguinal white adipose tissue (iWAT, F). (G-K) Plasma metabolic parameters: C-reactive protein (CRP, G), alanine aminotransferase (ALT, H), aspartate aminotransferase (AST, I), triglycerides (TG, J), and total cholesterol (TC, K). Data
[0043] Although the invention is described in terms of specific illustrative embodiments, it is to be understood that the embodiments described herein are by way of example only and that the scope of the invention is not intended to be limited thereby.
[0044] The present disclosure focuses on targeting G protein-coupled receptor 75 (GPR 75) as a therapeutic strategy against metabolic disorders, especially the metabolic disorders that have an association with GPR 75. The present disclosure describes compounds that are useful as an antagonist that specifically exhibited inhibitory effects on GPR75.
[0045] All terms are intended to be understood as they would be understood by a person skilled in the art. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the disclosure pertains. The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
[0046] Although various features of the present disclosure can be described in the context of a single embodiment, the features can also be provided separately or in any suitable combination. Conversely, although the present disclosure can be described herein in the context of separate embodiments for clarity, the present disclosure can also be implemented in a single embodiment.
[0047] The following definitions supplement those in the art and are directed to the current application. Accordingly, the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.
[0048] By “about”, it is meant that the value can vary within a certain range depending on the margin of error of the method or device used to evaluate or measure. A margin of error of 10% is generally accepted.
[0049] As used herein, the term "substantially" or "substantial," when used in reference to a change, reduction, increase, or difference in a measurable parameter, means a change, reduction, increase, or difference that is statistically significant (e g., p < 0.05) or that exceeds normal biological variability under the conditions of measurement. Conversely, when used in the negative (e.g., "does not substantially alter" or "remains substantially unchanged"), the term means that the parameter does not change by a statistically significant amount or does not changeby more than would be expected from normal biological variability under the conditions of measurement.
[0050] In this application, the use of the singular includes the plural unless specifically stated otherwise. It must be noted that, as used in the specification, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise.
[0051] Furthermore, use of the term "including" as well as other forms, such as "include", "includes," and "included," is not limiting.
[0052] Reference in the specification to "some embodiments," "an embodiment," "one embodiment" “alternate embodiment”, or "other embodiments" means that a particular feature, structure, or characteristic described in connection with the embodiments is included in at least some embodiments, but not necessarily all embodiments, of the present disclosures.
[0053] As used in this specification and claim(s), the words "comprising" (and any form of comprising, such as "comprise" and "comprises"), "having" (and any form of having, such as "have" and "has"), "including" (and any form of including, such as "includes" and "include") or "containing" (and any form of containing, such as "contains" and "contain") are inclusive or open-ended and do not exclude additional, unrecited elements or method steps. It is contemplated that any embodiment discussed in this specification can be implemented with respect to any method, use, or composition of the present disclosure, and vice versa. Furthermore, compositions of the present disclosure can be used to achieve methods or uses of the present disclosure.
[0054] " Patient" or "subject" as used herein refers to a mammalian subject diagnosed with or suspected of having or developing a medical condition, cellular defect or a disease or disorder. In some embodiments, the term "subject" refers to a mammalian subject, optionally a human subject, that has been diagnosed with, or is at risk for metabolic disease(s).
[0055] As used herein, the term "untreated control subject" refers to a subject that is matched to the treated subject in relevant characteristics (including, but not limited to, species, age, sex, body weight, dietary intake, and disease state) but that has not been administered the compound or has been administered a placebo or vehicle control in place of the compound.
[0056] As used herein, the term "baseline value" refers to a measurement of a given parameter obtained from the subject prior to the first administration of the compound or composition as described herein, preferably under conditions otherwise comparable to those at the time of the post-treatment measurement. The baseline value may relate to any clinically or experimentally measurable parameter, including, but not limited to, anthropometric parameters (e.g., body weight, body mass index), tissue or organ weights, histological parameters (e.g., adipocyte size), circulating biomarkers (e.g., plasma lipids, liver enzymes, inflammatory markers, apolipoproteins), fecal parameters (e.g., fecal lipid content, fecal protein content, fecal microbiome composition), functional parameters (e.g., intestinal permeability, energy expenditure, respiratory exchange ratio), or any other quantifiable physiological, biochemical, or molecular measurement relevant to the metabolic disease being treated or reduction of intestinal fat absorption, increase of fecal lipid excretion, modulation of gut microbiome composition, reduction of intestinal permeability, improvement of gut barrier integrity and / or reduction of chylomicron secretion being performed. A baseline value may be obtained from a single measurement, or from the mean or median of two or more measurements, taken prior to administration of the compound. When multiple baseline measurements are obtained, they may be taken on the same day or on different days, provided that the conditions of measurement are otherwise comparable to those at the time of the post-treatment measurement.
[0057] " Administering" is referred to herein as providing one or more compounds or compositions described herein to a patient or a subject. By way of example and not limitation, compound or composition administration, e g., injection, can be performed intravenous (i.v.) injection, sub-cutaneous (s.c.) injection, intradermal (i d.) injection, intraperitoneal (i.p.) injection, or intramuscular (i.m.) injection. One or more such routes can be employed. Alternatively, or concurrently, administration can be by the oral route or the rectal route.
[0058] As used herein, the term "treatment" or "treating" or its grammatical equivalents refers to obtaining a desired pharmacologic and / or physiologic effect. In embodiments, the effect is therapeutic, i.e., the effect partially or completely cures a disease and / or adverse symptom attributable to the disease.
[0059] As used herein, the term “therapeutically effective amount” refers to an amount effective in diagnosis, cure, mitigation, or prevention of disease.
[0060] As used herein, the term "antagonist" refers to a molecule that binds to G protein-coupled receptor 75 (GPR75) and inhibits, blocks, reduces, or otherwise attenuates one or more biological activities of GPR75.
[0061] As used herein, the term "metabolic disease" refers to any disease, disorder, syndrome or condition characterized by a disruption in normal metabolic processes, including, but not limited to, dysregulation of lipid metabolism, glucose metabolism, energy homeostasis, or body weight regulation. In some cases, the metabolic disease is associated with GPR75, which refers to a disease, disorder, syndrome or condition in which GPR75 signaling plays a causative, contributory, or modulatory role in disease pathology, disease mechanism and / or disease progression. Non-limiting examples of metabolic diseases include obesity, diet-induced obesity, type 2 diabetes (T2D), insulin resistance, non-alcoholic fatty liver disease (NAFLD), metabolic dysfunction-associated steatotic liver disease (MASLD), and cardiometabolic diseases.
[0062] As used herein, “metabolic disease associated with GPR75” a disease, disorder, syndrome or condition in which GPR75 signaling plays a causative, contributory, or modulatory role in the disease pathology, disease mechanism and / or disease progression.
[0063] As used herein, the term "pharmaceutically acceptable salt" refers to a salt of a compound described herein that is prepared with an acid or base that is non-toxic at the concentrations at which it is administered, and that does not substantially diminish the biological activity or properties of the compound. Pharmaceutically acceptable salts include acid addition salts formed with inorganic acids (e g., hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid) or organic acids (e.g., acetic acid, citric acid, fumaric acid, maleic acid, malic acid, succinic acid, tartaric acid, benzoic acid, p-toluenesulfonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, lactic acid, or ascorbic acid), as well as base addition salts formed with inorganic bases (e.g., sodium, potassium, lithium, calcium, magnesium, zinc, or aluminum hydroxides, carbonates, or bicarbonates) or organic bases (e.g., primary, secondary, or tertiary amines, including methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, lysine, arginine, choline, or procaine). The term further encompasses salts formed with pharmaceutically acceptable cations including, but not limited to, sodium, potassium, calcium, magnesium, zinc, aluminum, lithium, ammonium, meglumine, tromethamine (tris), or lysine cations.
[0064] As used herein, the term "solvate" refers to a crystalline or solid form of a compound described herein that is associated with one or more molecules of a solvent. The solvent molecules are incorporated into the crystal lattice of the compound in a defined stoichiometric or non-stoichiometric ratio. Suitable solvents include, but are not limited to, water, methanol, ethanol, isopropanol, acetone, ethyl acetate, acetonitrile, and dimethyl sulfoxide. When the solvent is water, the solvate is referred to as a “hydrate”. Hydrates may include but not limited to monohydrates, dihydrates, trihydrates, hemihydrates, sesquihydrates, and other stoichiometric or non-stoichiometric hydrates in which one or more water molecules are incorporated into the crystal lattice of the compound in a defined or variable ratio.
[0065] As used herein, the term "stereoisomer" refers to a compound that possesses the same molecular formula and sequence of bonded atoms (constitution) as the compound described herein, but differs in the three-dimensional spatial arrangement of its atoms. Stereoisomers include enantiomers (non-superimposable mirror images), diastereomers (stereoisomers that are not mirror images), geometric isomers (cis / trans or E / Z isomers), atropisomers (stereoisomers arising from restricted rotation about a single bond), and any individual stereoisomer or mixture of stereoisomers thereof, including racemic mixtures and scalemic mixtures. Where a compound described herein contains one or more stereocenters, the disclosure encompasses each individual stereoisomer, as well as any mixture of such stereoisomers in any proportion, unless otherwise specified.
[0066] As used herein, the term "monocyclic ring" refers to a single, non-fused ring structure comprising 3 to 6 ring atoms. The monocyclic ring may be a carbocyclic ring (in which all ring atoms are carbon) or a heterocyclic ring (in which one or more ring atoms are independently selected from N, O, and S, with the remaining ring atoms being carbon). Monocyclic carbocyclic rings include, but are not limited to, C3-C6 cycloalkyl rings such as cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl, as well as C3-C6 cycloalkenyl rings containing one or more degrees of unsaturation. Monocyclic heterocyclic rings include, but are not limited to, 3- to 6-membered saturated or partially unsaturated heterocyclic rings such as oxiranyl, aziridinyl, oxetanyl, azetidinyl, thietanyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydrothiophenyl, tetrahydropyranyl, piperidinyl, morpholinyl, piperazinyl, and thiomorpholinyl, as well as 5- to 6-membered heteroaromatic rings such as furanyl, thiophenyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, triazolyl, pyridinyl, pyrimidinyl, pyridazinyl, and pyrazinyl. The monocyclic ring may be unsubstituted or substituted with one or more substituents as described herein.
[0067] As used herein, the term "halogen" or "halo" refers to fluorine (F), chlorine (Cl), bromine (Br), or iodine (I).
[0068] As used herein, the term "alkyl" refers to a saturated, straight-chain or branched-chain hydrocarbon group. In some embodiments, the alkyl has from 1 to 12 carbon atoms (" C1-C12 alkyl"). In preferred embodiments, the alkyl has from 1 to 6 carbon atoms (" C1-C6 alkyl"). Other carbon chain lengths above, below, or in between are also contemplated. Non-limiting examples of alkyl groups include methyl (C1), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), isobutyl (C4), sec-butyl (C4), tert-butyl (C4), n-pentyl (C5), isopentyl (C5), neopentyl (C5), n-hexyl (C6), and isohexyl (C6). The alkyl group may be unsubstituted or substituted with one or more substituents as described herein. In some embodiments, the alkyl is substituted with one or more halogens. In certain such embodiments, the alkyl is substituted with one or more fluorine atoms to form a fluoroalkyl group, including, but not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 2,2-difluoroethyl, and 2,2,2-trifluoroethyl. In a preferred embodiment, the alkyl is methyl or ethyl.
[0069] The following embodiments represent preferred modes of carrying out the invention. These embodiments are provided by way of illustration and are not intended to limit the scope of the claims.
[0070] In a broad aspect, the present disclosure relates to a compound of formula I, formula II, formula III or formula IV, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof:(Formula I),(IV);wherein:X, Y, Z, and Q are independently C, S, O, or N;R1is a 3-6 membered monocyclic ring;R2is H or a halogen; andR3, R4, R5, and R6are independently H or Ci-C6alkyl, optionally the Ci-C6alkyl is substituted with one or more halogens.
[0071] In another broad aspect, the present disclosure relates to a method of treating a metabolic disease in a subject, the method comprising administering a therapeutically effective amount of a compound of formula I, formula II, formula III or formula IV, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, to the subject in need thereof:wherein:X, Y, Z, and Q are independently C, S, O, or N;R1is a 3-6 membered monocyclic ring;R2is H or a halogen; andR3, R4, R5, and R6are independently H or Ci-Ce alkyl, optionally the Ci-Ce alkyl is substituted with one or more halogens.
[0072] In another broad aspect, the present disclosure relates to a compound of formula I, formula II, formula III or formula IV, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, for use in treating a metabolic disease in a subject in need thereof, wherein the compound is for administration to the subject:formula (IV);wherein:X, Y, Z, and Q are independently C, S, O, or N;R1is a 3-6 membered monocyclic ring;R2is H or a halogen; andR3, R4, R5, and R6are independently H or Ci-C6alkyl, optionally the Ci-C6alkyl is substituted with one or more halogens.
[0073] In another broad aspect, the present disclosure relates to a method of reducing intestinal fat absorption, increasing fecal lipid excretion, modulating gut microbiome composition, reducing intestinal permeability, improving gut barrier integrity and / or reducing chylomicron secretion in a subject, the method comprises administering a therapeutically effective amount of a compound of formula I, formula II, formula III or formula IV, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, to the subject in need thereof:(IV);wherein:X, Y, Z, and Q are independently C, S, O, or N;R1is a 3-6 membered monocyclic ring;R2is H or a halogen; andR3, R4, R5, and R6are independently H or Ci-C6alkyl, optionally the Ci-C6alkyl is substituted with one or more halogens.
[0074] In another broad aspect, the present disclosure relates to a compound of formula I, formula II, formula III or formula IV, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, for use in reducing intestinal fat absorption, increasing fecal lipid excretion, modulating gut microbiome composition, reducing intestinal permeability, improving gut barrier integrity and / or reducing chylomicron secretion in a subject:formula (IV);wherein:X, Y, Z, and Q are independently C, S, O, or N;R1is a 3-6 membered monocyclic ring;R2is H or a halogen; andR3, R4, R5, and R6are independently H or Ci-C6alkyl, optionally the Ci-C6alkyl is substituted with one or more halogens.
[0075] In another broad aspect, the present disclosure relates to a compound of formula I, formula II, formula III or formula IV, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, for use in the manufacture of a medicament for treatment of a metabolic disease in a subject:(Formula I),(IV);wherein:X, Y, Z, and Q are independently C, S, O, or N;R1is a 3-6 membered monocyclic ring;R2is H or a halogen; andR3, R4, R5, and R6are independently H or Ci-C6alkyl, optionally the Ci-C6alkyl is substituted with one or more halogens.
[0076] In another broad aspect, the present disclosure relates to use of a compound of formula I, formula II, formula III or formula IV, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, for treatment of a metabolic disease in a subject:X, Y, Z, and Q are independently C, S, O, or N;R1is a 3-6 membered monocyclic ring;R2is H or a halogen; andR3, R4, R5, and R6are independently H or Ci-C6alkyl, optionally the Ci-C6alkyl is substituted with one or more halogens.
[0077] In some embodiments, in the compound of formula I, formula III or formula IV, X and Y are both N or both S.
[0078] In some embodiments, in the compound of formula II, formula III or formula IV, Z and Q are both N.
[0079] In some embodiments, in the compound of formula I, R1is a C3-C6cycloalkyl.
[0080] In some embodiments, in the compound of formula I, formula III or formula IV, R2is Cl or F.
[0081] In some embodiments, in the compound of formula II or formula III, R3is a Ci or C2alkyl.
[0082] In some embodiments, in the compound of formula II or formula IV, R4and R5are both methyl groups. In a preferred embodiment, in the compound of formula II, R4and R5are both methyl groups further substituted with one or more halogens. In a more preferred embodiment, in the compound of formula II, R4and R5are both methyl groups further substituted with two F.
[0083] In some embodiments, in the compound of formula IV, both R3and R6are ethyl groups.
[0084] In some embodiments, in the compound of formula IV, X, Y, Z, Q are all N.
[0001] The compounds described herein may be prepared by synthetic methods known in the art. One of ordinary skill in the art would readily appreciate that the compounds of the present disclosure can be synthesized using standard organic chemistry techniques. In some embodiments, the compounds described herein may be prepared by one or more synthetic transformations known in the art, including but not limited to N-alkylation, N-arylation, C-N bondformation, amide coupling, acylation, nucleophilic aromatic substitution, thioalkylation, S-alkylation, cyclocondensation, ring formation, and heterocyclic ring construction. Such transformations may be carried out under standard conditions, including but not limited to the use of transition-metal catalysis (e.g., palladium- or copper-catalyzed coupling reactions), coupling reagents (e.g., EDCI, HATU, DCC, or HOBt), bases (e.g., triethylamine, diisopropylethylamine, potassium carbonate, sodium hydride, or cesium carbonate), and suitable solvents (e.g., DMF, DMSO, THF, DCM, acetonitrile, or toluene). One of ordinary skill in the art would recognize that the compounds described herein, including benzothiadiazole-2, 2-dione, tetrahydroazulene, diazatricyclic thiaene, and pyridazinone scaffolds, may be assembled by sequential functionalization of a core heterocyclic or carbocyclic ring system with the appropriate substituents (e.g., alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, aryloxy, or thioether groups) using the transformations described above or equivalents thereof.
[0002] In some embodiments, the compound of formula I, formula II, formula III or formula IV is:or a pharmaceutically acceptable salt, solvate, hydrate, or stereoisomer thereof.
[0003] In another broad aspect, the present disclosure relates to a compound of:or a pharmaceutically acceptable salt, solvate, hydrate, or stereoisomer thereof.
[0004] In another broad aspect, the present disclosure relates to a method of treating a metabolic disease in a subject, comprising administering a therapeutically effective amount of the following compound:or a pharmaceutically acceptable salt, solvate, hydrate, or stereoisomer thereof, to the subject in need thereof.
[0005] In another broad aspect, the present disclosure relates to a method of reducing intestinal fat absorption, increasing fecal lipid excretion, modulating gut microbiome composition, reducing intestinal permeability, improving gut barrier integrity and / or reducing chylomicron secretion in a subject, the method comprises administering a therapeutically effective amount of the following compound to the subject in need thereof:or a pharmaceutically acceptable salt, solvate, hydrate, or stereoisomer thereof.
[0006] Compound as antagonists of GPR 75
[0007] In some embodiments, the compound as described herein or hereabove, is an antagonist of the G protein-coupled receptor 75 (GPR75). The antagonist may act by any mechanism that results in diminished GPR75 signaling, including, but not limited to, binding to the orthosteric site of GPR75 and preventing binding of an endogenous or exogenous agonist; binding to an allosteric site of GPR75 and reducing the receptor's responsiveness to agonist stimulation; suppressing GPR75 activation-stimulated p-arrestin recruitment; or inhibiting downstream G-protein-mediated signal transduction pathways associated with GPR75 activation.
[0008] In some embodiments, an antagonist of GPR75 is identified and / or characterized using any method known in the art. As a non-limiting example, an antagonist of GPR75 is identified and / or characterized by its ability to suppress p-arrestin recruitment to GPR75 in a p-arrestin recruitment assay, such as the PathHunter p-arrestin recruitment assay (DiscoverX), when GPR75 is stimulated with a crude ligand solution or a known agonist.
[0009] In some embodiments, the compound described herein or hereabove inhibits GPR75 activity in a dose-dependent manner, which for example, can be measured by IC50 determination in such an assay. In some embodiments, the compound exhibits an IC50 of less than 10 μM, 5 μM, 2 μM, or 1 μM for inhibition of GPR75. Other IC50 values above, below or in between are also contemplated.
[0010] In some embodiments, the compound described herein or hereabove selectively inhibits GPR75. As used herein, “"selectively inhibits" or "selective inhibition" with respect to GPR75 means that the antagonist exhibits a substantially greater inhibitory potency (e.g., as measured by IC50) or binding affinity (e.g., as measured by Ki or Kd) for GPR75 as compared to one or more other G protein-coupled receptors.
[0011] In some embodiments, the compound as described herein or hereabove selectively inhibits GPR75 with at least 2-fold, at least 5-fold, at least 10-fold, at least 20-fold, at least 50-fold, or at least 100-fold greater potency for GPR75 relative to one or more other G protein-coupled receptors, as determined by a suitable functional or binding assay. Other fold values above, below or in between are also contemplated. In a preferred embodiment, the compound selectively inhibits GPR75 with at least 2-fold, at least 5-fold, at least 10-fold, at least 20-fold, at least 50-fold, or at least 100-fold greater potency for GPR75 relative to GPR 146.
[0012] Compound for treating metabolic diseases
[0013] In some embodiments, the compound as described herein or hereabove is for use in treating a metabolic disease in a subject.
[0014] In some embodiments, the metabolic disease is a G protein-coupled receptor 75 associated metabolic disease.
[0015] In some embodiments, the metabolic disease is obesity, type 2 diabetes (T2D), insulin resistance, cardiovascular disease (CVD), metabolic dysfunction-associated steatotic liverdisease (MASLD), non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), metabolic syndrome, dyslipidemia, hypertriglyceridemia, hypercholesterolemia, atherosclerosis, hyperglycemia, glucose intolerance, visceral adiposity, hepatic steatosis, metabolic dysfunction-associated steatohepatitis (MASH), obesity-related hypertension, diabetic kidney disease, obesity-associated cancer, polycystic ovary syndrome (PCOS), lipodystrophy, chylomicronemia, postprandial hyperlipidemia, or any combination thereof. In a preferred embodiment, the metabolic disease is obesity, Type 2 Diabetes (T2D), cardiovascular disease (CVD), Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) I Non-Alcoholic Fatty Liver Disease (NAFLD), or insulin resistance or a combination thereof. Even more preferably, the metabolic disease is obesity, liver disease (e.g. MASLD / NAFLD, and NASH / MASH) or a combination thereof.
[0016] In some embodiments, the metabolic disease is obesity. In certain such embodiments, the obesity is diet-induced obesity. In further embodiments, the obesity is characterized by excessive fat accumulation, elevated body mass index (BMI), increased white adipose tissue mass, increased brown adipose tissue mass, increased adipocyte size, or any combination thereof. In certain such embodiments, treating obesity comprises reducing body weight, reducing cumulative body weight gain, reducing epididymal white adipose tissue (eWAT) mass, reducing inguinal white adipose tissue (ingWAT) mass, reducing interscapular brown adipose tissue (iBAT) mass, reducing fat accumulation in iBAT, reducing adipocyte size in one or more of eWAT and ingWAT, or any combination thereof.
[0017] In some embodiments, treating obesity comprises reducing body weight by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, or at least 45% relative to an untreated control subject or relative to the subject's own baseline value measured prior to administration of the compound. Other percentages above, below, or in between are also contemplated. In some embodiments, treating obesity comprises; reducing epididymal white adipose tissue (eWAT) mass by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, or at least 64% relative to an untreated control subject or relative to the subject's own baseline value measured prior to administration of the compound; reducing inguinal white adipose tissue (ingWAT) mass by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, or at least 66% relative to an untreated control subject or relative to the subject's own baseline value measured prior to administration of the compound; or reducing interscapular brown adipose tissue (iBAT) mass by at least 5%, at least 10%, at least 15%, at least 25%, at least 35%, or at least 43% relative to an untreated control subject or relative to the subject's own baseline valuemeasured prior to administration of the compound. Other percentages above, below, or in between are also contemplated. In some embodiments, treating obesity comprises any combination as mentioned above.
[0018] In some embodiments, the compound as described herein or hereabove, through GPR75 antagonism, regulates diet-induced obesity through coordinated multi-organ mechanisms rather than through a single tissue-autonomous mechanism. In certain such embodiments, the multi-organ mechanisms involve coordinated signaling between the central nervous system and the gastrointestinal tract. In further embodiments, the coordinated multi-organ mechanisms involve brain-to-gut communication pathways that modulate intestinal lipid absorption.
[0019] In some embodiments, the metabolic disease is a liver disease associated with metabolic dysfunction. In certain such embodiments, the liver disease is MASLD or NAFLD, and treating the liver disease comprises reducing hepatic triglyceride levels, reducing hepatic cholesterol levels, reducing liver weight, reducing blood alanine aminotransferase (ALT) levels, reducing blood aspartate aminotransferase (AST) levels, or any combination thereof. In some embodiments, treating the liver disease comprises reducing hepatic triglyceride levels by at least 20%, at least 40%, at least 47%, or at least 58% or at least 65% relative to an untreated control subject or relative to the subject's own baseline value measured prior to administration of the compound. Other percentages above, below, or in between are also contemplated. In some embodiments, treating the liver disease comprises reducing liver weight by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, or at least 34% relative to an untreated control subject or relative to the subject's own baseline value measured prior to administration of the compound. In some embodiments, treating the liver disease comprises a combination as mentioned above.
[0020] In some embodiments, the subject has been diagnosed with, or is at risk for, two or more metabolic diseases as described herein. In certain such embodiments, treating the subject comprises achieving one or more of the therapeutic outcomes described herein with respect to each of the two or more metabolic diseases upon administration of the compound. In further embodiments, the compound is administered in a single therapeutic regimen that is effective to treat the two or more metabolic diseases simultaneously in the subject. Non-limiting examples of comorbid metabolic disease combinations include obesity and a liver disease associated with metabolic dysfunction (e g., MASLD or NAFLD); obesity and type 2 diabetes (T2D); obesity and dyslipidemia; obesity and cardiovascular disease (CVD); obesity and insulinresistance; type 2 diabetes and a liver disease associated with metabolic dysfunction; type 2 diabetes and dyslipidemia; type 2 diabetes and cardiovascular disease; metabolic syndrome and a liver disease associated with metabolic dysfunction; and any combination of three or more of the foregoing. In a preferred embodiment, the subject has been diagnosed with, or is at risk for, both obesity and a liver disease associated with metabolic dysfunction (e.g., MASLD or NAFLD), and treating the subject comprises achieving one or more of the therapeutic outcomes described herein with respect to treating obesity (e g., reducing body weight, reducing cumulative body weight gain, reducing eWAT mass, reducing ingWAT mass, reducing iBAT mass, reducing adipocyte size) and one or more of the therapeutic outcomes described herein with respect to treating the liver disease (e.g., reducing hepatic triglyceride levels, reducing hepatic cholesterol levels, reducing liver weight, reducing ALT levels, reducing AST levels), concurrently or sequentially, upon administration of the compound.
[0021] In some embodiments, treating the metabolic disease further comprises reducing circulating C-reactive protein (CRP) levels in the subject. In certain such embodiments, the reduction in CRP levels is indicative of a reduction in systemic inflammation associated with the metabolic disease.
[0022] In some embodiments, treating the metabolic disease comprises modulating the gut microbiome composition of the subject. In certain such embodiments, modulating the gut microbiome composition comprises reducing the relative abundance of Firmicutes, increasing the relative abundance of Bacteroidetes, reducing the relative abundance of Actinobacteria, reducing the Firmicutes-to- Bacteroidetes ratio, or any combination thereof. In further embodiments, the modulation of gut microbiome composition results in a microbial composition associated with a lean phenotype and reduced energy harvest capacity.
[0023] In some embodiments, treating the metabolic disease comprises reducing intestinal permeability in the subject. In certain such embodiments, reduced intestinal permeability is characterized by a decrease in circulating FITC-dextran levels following oral administration of FITC-dextran relative to an untreated control subject, indicating improved gut barrier integrity.
[0024] In some embodiments, treating the metabolic disease comprises impairing intestinal absorption of both dietary lipids and dietary protein in the subject, resulting in a systemic defect in nutrient absorption. In certain such embodiments, fecal protein excretion is increased relative to an untreated control subject.
[0025] In some embodiments, the fecal triglyceride-to-free fatty acid ratio remains unchanged relative to an untreated control subject, which may indicate that hydrolysis of dietary triglycerides by pancreatic lipase is not substantially affected by administration of the compound.
[0026] In some embodiments, treating the metabolic disease comprises two or more of the foregoing therapeutic outcomes occurring concurrently in the subject. For example, and without limitation, treating the metabolic disease may comprise reducing circulating CRP levels and modulating gut microbiome composition; reducing intestinal permeability and modulating gut microbiome composition; reducing intestinal lipid absorption, increasing fecal lipid excretion, and reducing circulating CRP levels; modulating gut microbiome composition, reducing intestinal permeability, and impairing intestinal absorption of both dietary lipids and dietary protein; or any other combination of two or more of the therapeutic outcomes described herein. In some embodiments, it is contemplated that GPR75 antagonism may produce multiple therapeutic outcomes simultaneously, reflecting the coordinated, multi-organ mechanisms by which GPR75 regulates metabolic homeostasis.
[0027] Compound for use in reducing intestinal fat absorption, increasing fecal lipid excretion, modulating gut microbiome composition, reducing intestinal permeability, improving gut barrier integrity and / or reducing chylomicron secretion
[0028] In some embodiments, the compound as described herein or hereabove is for use in reducing intestinal fat absorption, increasing fecal lipid excretion, modulating gut microbiome composition, reducing intestinal permeability, improving gut barrier integrity and / or reducing chylomicron secretion in a subject, wherein the compound is for administration to a subject in need thereof.
[0029] In some embodiments, modulating the gut microbiome composition comprises reducing the relative abundance of Firmicutes, increasing the relative abundance of Bacteroidetes, reducing the relative abundance of Actinobacteria, reducing the Firmicutes-to-Bacteroidetes ratio, or any combination thereof. In certain such embodiments, the modulation results in a microbial composition associated with a lean phenotype and reduced energy harvest capacity. In some embodiments, modulating the gut microbiome composition further results in one or more of reduced body weight, reduced adiposity, reduced hepatic steatosis, or improved metabolic parameters in the subject.
[0030] In some embodiments, reducing intestinal permeability and / or improving gut barrier integrity is characterized by a decrease in circulating FITC-dextran levels following oral administration of FITC-dextran relative to an untreated control subject or relative to the subject's own baseline value measured prior to administration of the compound. In some embodiments, reducing intestinal permeability and / or improving gut barrier integrity further comprises upregulation of one or more pathways related to cell-cell junction assembly in the intestine of the subject.
[0031] In some embodiments, reducing intestinal fat absorption comprises reducing the absorption of dietary triglycerides, dietary free fatty acids, or both, from the intestinal lumen into the circulation of the subject. In certain such embodiments, reducing intestinal fat absorption results in a measurable decrease in plasma triglyceride levels, optionally postprandial plasma triglyceride levels, relative to an untreated control subject or relative to the subject's baseline plasma triglyceride levels prior to administration of the compound.
[0032] In some embodiments, reducing chylomicron secretion comprises reducing the assembly, secretion, or circulating levels of chylomicron particles in the subject. In certain such embodiments, reducing chylomicron secretion is characterized by a reduction in circulating apolipoprotein B48 (ApoB48) levels in the subject following administration of the compound, as compared to an untreated control subject or as compared to the subject's baseline ApoB48 levels prior to administration. In some embodiments, circulating apolipoprotein B100 (ApoB100) levels are not substantially altered by administration of the compound.
[0033] In some embodiments, increasing fecal lipid excretion comprises increasing the total daily fecal content of one or more of triglycerides, total cholesterol, and free fatty acids in the subject. In certain such embodiments, fecal lipid excretion is increased by at least about 10%, at least about 25%, at least about 50%, or at least about 100% relative to an untreated control subject or relative to the subject's baseline fecal lipid excretion prior to administration of the compound. In some embodiments, the increase in total daily fecal lipid excretion is attributable to an increase in total daily fecal output rather than to an increase in relative fecal lipid concentration. In some embodiments, total daily fecal weight is increased by at least 25%, at least 30%, or at least 35% relative to an untreated control subject or relative to the subject's own baseline value measured prior to administration of the compound. Other percentages above, below, or in between are also contemplated.
[0034] In some embodiments, the methods, uses, and / or the compound for uses as described herein or hereabove reduces body weight, reduces cumulative body weight gain, reduces epididymal white adipose tissue (eWAT) mass, reduces inguinal white adipose tissue (ingWAT) mass, reduces interscapular brown adipose tissue (iBAT) mass, reduces fat accumulation in iBAT, reduces adipocyte size in one or more of eWAT and ingWAT, reduces liver weight, reduces hepatic triglyceride content, reduces hepatic cholesterol levels, reduces blood alanine aminotransferase (ALT) levels, reduces blood aspartate aminotransferase (AST) levels, reduces circulating C-reactive protein (CRP) levels, reduces circulating triglyceride levels, reduces circulating total cholesterol levels, or any combination thereof.
[0035] In a preferred embodiment, the baseline measurement is obtained prior to the first administration of the compound under conditions otherwise comparable to those at the time of the post-treatment measurement.
[0036] In some embodiments, the compounds described herein is for use in treating metabolic diseases or for use in reducing intestinal fat absorption, increasing fecal lipid excretion, modulating gut microbiome composition, reducing intestinal permeability, improving gut barrier integrity and / or reducing chylomicron secretion may be obtained from commercial or other sources.
[0037] Pharmaceutical compositions
[0038] In some embodiments, there is provided herein a pharmaceutical composition comprising any one or more of the compounds as described herein or hereabove, together with one or more pharmaceutically acceptable carriers, diluents or excipients. The pharmaceutical composition may optionally comprise one or more additional therapeutic agents.
[0039] The pharmaceutical composition may be formulated using conventional carriers and excipients selected in accordance with ordinary pharmaceutical practice. Excipients include, but are not limited to, antioxidants such as ascorbic acid, chelating agents such as ethylenediaminetetraacetic acid (EDTA), carbohydrates such as hydroxyalkylcellulose, hydroxyalkylmethylcellulose and dextrin, and stearic acid. The pH of the pharmaceutical compositions typically ranges from about 3 to about 11, preferably from about 7 to about 10. Reference is made to the Handbook of Pharmaceutical Excipients (Rowe et al., eds.), incorporated herein by reference, for further guidance on suitable excipients.
[0040] The pharmaceutical composition may be prepared by any method known in the art, including bringing the compound into association with the carrier, optionally with one or more accessory ingredients, and then shaping the product if necessary. Reference is made to Remington: The Science and Practice of Pharmacy (Mack Publishing Co., Easton, Pa.), incorporated herein by reference, for general guidance on pharmaceutical formulation techniques.
[0041] In some embodiments, the compound or composition is administered to the subject in a therapeutically effective amount. In certain such embodiments, the compound or composition is administered orally. In some embodiments, the compound or composition is formulated as an oral dosage form suitable for targeting GPR75 in the gastrointestinal (Gl) tract of the subject.
[0042] Pharmaceutical compositions suitable for oral administration include discrete units such as capsules, cachets or tablets, each containing a predetermined amount of the compound; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; and oil-in-water or water-in-oil emulsions.
[0043] Tablets may be prepared by compression or molding, optionally with one or more accessory ingredients such as binders, lubricants, inert diluents, preservatives, or surface-active or dispersing agents. Tablets may be uncoated or coated by known techniques, including microencapsulation, to provide sustained release of the active ingredient.
[0044] Capsules may be hard gelatin capsules containing the active ingredient mixed with an inert solid diluent, or soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium such as peanut oil, liquid paraffin or olive oil.
[0045] Tablets may comprise non-toxic pharmaceutically acceptable excipients including inert diluents such as calcium or sodium carbonate, lactose, calcium or sodium phosphate; granulating and disintegrating agents such as maize starch or alginic acid; binding agents such as cellulose, microcrystalline cellulose, starch, gelatin or acacia; and lubricating agents such as magnesium stearate, stearic acid or talc.
[0046] Aqueous suspensions contain the compound in admixture with excipients suitable for their manufacture, including suspending agents such as sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; and dispersing or wetting agents such as naturally occurring phosphatides (e g., lecithin), condensation products of alkylene oxides with fatty acids (e.g.,polyoxyethylene stearate), and condensation products of ethylene oxide with long chain aliphatic alcohols or with partial esters derived from fatty acids and hexitol anhydrides. Aqueous suspensions may also contain preservatives, coloring agents, flavoring agents and sweetening agents.
[0047] Oil suspensions may be formulated by suspending the compound in a vegetable oil such as arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin, optionally with a thickening agent such as beeswax, hard paraffin or cetyl alcohol. Sweetening and flavoring agents may be added to provide a palatable preparation, and antioxidants such as ascorbic acid may be included as preservatives.
[0048] Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water comprise the compound in admixture with a dispersing or wetting agent, a suspending agent, and optionally one or more preservatives, sweetening, flavoring and coloring agents.
[0049] Oil-in-water emulsions comprise an oily phase (such as olive oil, arachis oil, mineral oil, or mixtures thereof) and suitable emulsifying agents including naturally-occurring gums, naturally occurring phosphatides, and sorbitan esters or their polyoxyethylene derivatives. Syrups and elixirs may be formulated with sweetening agents such as glycerol, sorbitol or sucrose, and may contain demulcents, preservatives, flavoring and coloring agents.
[0050] Pharmaceutical compositions for rectal administration may be presented as suppositories with a suitable base comprising, for example, cocoa butter or a salicylate.
[0051] The pharmaceutical compositions may be presented in unit-dose or multi-dose containers, such as sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of a sterile liquid carrier immediately prior to use. Unit dosage pharmaceutical compositions preferably contain a daily dose or unit daily sub-dose of the active ingredient, or an appropriate fraction thereof.
[0052] The pharmaceutical compositions may include other agents conventional in the pharmaceutical art, such as flavoring agents for oral administration.
[0053] The pharmaceutical compositions may be formulated to provide controlled or sustained release of the active ingredient, allowing less frequent dosing or improved pharmacokinetic or toxicity profiles.
[0054] In some embodiments, the compound or composition is administered at a dose of from about 0.01 mg / kg to about 100 mg / kg body weight of the subject. In certain such embodiments, the compound is administered at a dose of from about 0.1 mg / kg to about 50 mg / kg. In further embodiments, the compound is administered at a dose of about 1 mg / kg, about 2 mg / kg, about 3 mg / kg, about 4 mg / kg, about 5 mg / kg, about 6 mg / kg, about 7 mg / kg, about 8 mg / kg, about 9 mg / kg, or about 10 mg / kg, preferably about 5mg / kg. Other dosages above, below, or in between are also contemplated.
[0055] In some embodiments, the effective dose of the compound or composition depends on the nature of the condition being treated, toxicity, whether the compound is being used prophylactically or therapeutically, the method of delivery, and the pharmaceutical composition, and can be determined by the clinician using conventional dose escalation studies. EXAMPLES
[0056] These examples are provided to enable a person skilled in the art to practice the invention and are for illustrative purposes only. The examples are not meant to limit the scope of the compounds, methods or uses described herein, and the disclosure may be practiced otherwise than as specifically described.EXAMPLE-1 Global GPR75 deficiency protects against diet-induced obesity in part through impaired dietary lipid assimilation
[0057] Introduction
[0058] GPR75 is highly expressed in the central nervous system, including agoutirelated peptide (AgRP) and neuropeptide Y (Npy) neurons, which play critical roles in appetite regulation and energy balance4. Recent work using Nestin-Cre-mediated neuronal deletion demonstrated that neuron-specific loss of Gpr75 is sufficient to protect against HFD-induced obesity, primarily through reduced food intake and modest increases in energy expenditure8. However, under prolonged high-fat feeding, these neuronal knockout mice exhibited depot-specific adipose tissue remodeling, characterized by unchanged subcutaneous fat mass but significantly increasedvisceral fat mass and largely preserved adipocyte size in both depots8. These phenotypes differ substantially from those observed in global knockout models, which display marked reductions in overall adiposity and adipocyte size. Together, these findings indicate that neuronal GPR75 signaling plays an important role in energy balance, but may not fully account for the systemic metabolic adaptations observed in global deletion models, suggesting additional contributions from non-neuronal tissues or coordinated inter-organ mechanisms.
[0059] In addition to the brain, GPR75 is expressed in peripheral tissues, including the intestine4’7. The intestine plays a central role in nutrient absorption and chylomicron production, processes essential for dietary lipid assimilation. Whether peripheral GPR75 signaling contributes to energy extraction and adiposity has not been clearly defined. In this study, we performed a comprehensive physiological characterization of CRISPR-generated Gpr75 global knockout (GKO) mice under chow and high-fat diet conditions. The inventors found that, despite high brain expression, global GPR75 deficiency did not alter food intake during the early divergence of body weight. Instead, GKO mice exhibited reduced energy expenditure, increased respiratory exchange ratio (RER), markedly reduced intestinal chylomicron output, and increased fecal lipid excretion, indicating impaired dietary lipid assimilation under HFD feeding.
[0060] Collectively, these findings suggest that while neuronal GPR75 contributes to energy balance, the full protection against diet-induced obesity observed in global Gpr75 deficiency likely reflects coordinated, multi-organ regulation rather than a single dominant tissue-autonomous mechanism. The results therefore redefine GPR75 as a systemic regulator of energy extraction efficiency and adiposity, operating through complex interactions between central and peripheral tissues.
[0061] Methods
[0062] Mice and diet
[0063] All animal care and experimental procedures used in this study were approved by the Institutional Animal Care and Use Committee at the National University of Singapore (Protocol number R20-1518). Mice were housed under a 12h light-dark cycle in a temperature and humidity-controlled environment (21-23°C, 45-55%). Mice were maintained on normal chow diet or high-fat diet (HFD, 60% fat; TD.06414; Envigo) and with free access to water. Both male and female 6- to 37-week-old mice were used in this study as reported.
[0064] Gpr75+ / -, loxp / loxp knockin mice (Gpr75fl / fl), and Agrp-Cre mice were obtained from Cyagen Biosciences at 8 weeks of age. Albumin-Cre (The Jackson Laboratory, RRID: IMSR_JAX:003574), Tie2-Cre (The Jackson Laboratory, RRID: IMSR_JAX:008863), Villin-Cre (The Jackson Laboratory, RRID: IMSR_JAX:004586) mice were obtained from Jackson Laboratory at 8 weeks of age.
[0065] Gpr75+ / +and Gpr75- / -littermates were generated by breeding Gpr75+ / -mice. Liver-specific, enterocyte-specific, endothelial / hematopoietic-specific, or AgRP neuron-specific knockout mice were generated by crossing Gpr75‘''nwith Albumin-Cre, Villin-Cre, Tie2-Cre, or Agrp-Cre transgenic mice, respectively.
[0066] Indirect Calorimetry
[0067] All experiments were performed at room temperature of 21-23°C on a 12h lightdark cycle in a PhenoMaster System (TSE systems, Bad Homburg, Germany). Mice were single housed in open-circuit metabolic chambers and allowed to acclimatize to the new housing condition for 1 week prior to experiment. Weight of food and volume of water consumed, gas exchange, and activity levels were measured consecutively for 4 days under chow diet and 3 days under HFD. Prior to measurement under HFD, the mice were allowed to recover for 7 days, followed by HFD habituation for another 7 days.
[0068] Body temperature measurement
[0069] Mice were fasted overnight (14-16h) and refed for 6 h. Body temperature was measured using RET-3 rectal probe (Physitemp) attached to a Type-J / K / T / R / S Handheld Thermocouple Thermometer (Digi-Sense).
[0070] Oral lipid tolerance assay
[0071] Mice were fasted for 4h followed by 200pl olive oil or 30ug BODIPY-labelled fatty acid (BODIPY™ 500 / 510 C1, C12 (4,4-Difluoro-5-Methyl-4-Bora-3a,4a-Diaza-s-lndacene-3-Dodecanoic Acid) in 200uL olive oil via oral gavage. Blood samples were taken from tail vein right before and at different time points after oral gavage as reported. Plasma triglyceride (TG) was then isolated to measure TG levels using Infinity Triglycerides Reagent (Thermo Scientific, TR22421) or Triglyceride Colorimetric Assay Kit (Elabscience, E-BC-K261-M). BODIPY level inthe plasma was measured using a plate reader (Varioskan Flash, Thermo Scientific) with an excitation wavelength of 492 nm and emission wavelength of 520 nm.
[0072] Whole gut transit time assay
[0073] Mice were fasted overnight (14-16h) and gavage with 200μl of 6% Carmine Red (Sigma-Aldrich, C1022) dissolved in 0.5% methylcellulose (Sigma-Aldrich, M0512) solution. Subsequently, the mice are individually housed in a clean cage with free access to food and water. Whole gut transit time is calculated as the time interval between the gavage and the first observed red fecal pellet.
[0074] Intestinal permeability assay
[0075] Mice were fasted overnight (14-16h) and gavage with 200μl of 10mg / ml FITC-Dextran 4KDa (Sigma-Aldrich, 46944) in PBS. Blood samples were collected from tail vein right before and at different time points after oral gavage as reported. Plasma FITC-Dextran levels were measured using a plate reader (Varioskan Flash, Thermo Scientific) with an excitation wavelength of 485 nm and emission wavelength of 535 nm.
[0076] Blood lipid assays
[0077] Blood was collected from tail tips after 4h of fasting and plasmas were isolated via centrifugation. Triglyceride (TG) was measured using Infinity Triglycerides Reagent (Thermo Scientific, TR22421) or Triglyceride Colorimetric Assay Kit (Elabscience, E-BC-K261-M). Total cholesterol (TC) was measured using Infinity Cholesterol Reagent (Thermo Scientific, TR13421) and free fatty acid (FFA) was measured by Free Fatty Acid Assay Kit (Abeam, ab65341).
[0078] Blood glucose analysis
[0079] Mice were fasted for 4h or overnight (14-16h) as specified. Blood was collected from tail tips and blood glucose was measured using handheld glucometer, Accu-Chek Instant (Roche).
[0080] Western blotting analysis
[0081] Mouse plasma samples were analysed for ApoB-48 and ApoB-100 level. 2uL of serum subjected to SDS-PAGE using standard protocol. Blots were blocked for 1h with 5%Blotting-Grade Blocker (Bio-Rad, 1706404) in TBST (1X TBS and 0.1% Tween-20) and were incubated overnight with anti-apoB antibody (Santa Cruz Biotechnology, sc-393636, 1:1000) diluted in 5% Blotting-Grade Blocker in TBST at 4°C. Blots were washed three times with TBST, followed by HRP-conjugated secondary antibody (Anti-mouse IgG, Cell Signalling, 7076, 1:2000) incubation for 1 h at room temperature. Blots were visualised using ECL detection reagent (Clarity Western ECL Substrate, Bio-Rad, 1705061). Quantification was performed using Fiji ImageJ software24.
[0082] Tissues and fecal lipids analysis
[0083] Tissues were excised and snap-frozen in liquid nitrogen immediately and subsequently stored at -80°C. Fecal pellets were picked up from the cage using forceps, and stored at -80°C. The protocol for lipid extraction uses folch’s extraction method with minor modifications25. Briefly, 50mg of snap-frozen tissues (liver, duodenum, jejunum, and ileum) were homogenized in 500pl of ice-cold PBS. 200pl of the homogenate was transferred into 1200pl of chloroform: methanol (2:1; v / v) mixture followed by vigorous vortex for 30s, followed by addition of 100μl of ice-cold PBS into the mixture and mixed vigorously for 15s. Similarly, 50mg of dried, pulverized feces were mixed with 200pl of ice-cold PBS, and vortex vigorously for 60s. The mixture is then transferred into 1200pl of chloroform: methanol (2:1; v / v) mixture. The mixture was then centrifuged at 4,200 rpm for 10 min at 4°C. 200pl of the organic phase (bottom layer) was transferred into a new tube and evaporated in the fume hood till completely dry. The dried pellet is dissolved in 100μl 1% Triton X-100 in ethanol using constant rotation for 1h, and subsequently dried using a speedVac vacuum concentrator before dissolving in 100μl of 1% triton X-100 in PBS. TG and TC levels were measured using Infinity Triglycerides Reagent (Thermo Scientific, TR22421) or Triglyceride Colorimetric Assay Kit (Elabscience, E-BC-K261-M) and Infinity Cholesterol Reagent (Thermo Scientific, TR13421) respectively, according to manufacturer’s instructions. FFA level was measured by Free Fatty Acid Assay Kit (Abeam, ab65341), based on manufacturer’s instructions.
[0084] For tissue BODIPY measurement, 50mg of snap frozen small intestinal tissues (duodenum, jejunum, and ileum) were homogenised in 500μl of ice-cold RIPA buffer. The mixture was then centrifuged at 4,200 rpm for 10 min at 4°C. Measure the BODIPY fluorescent signal in the supernatant using a plate reader (Varioskan Flash, Thermo Scientific) with an excitation wavelength of 492 nm and emission wavelength of 520 nm.
[0085] Fecal protein analysis
[0086] To analyze fecal protein level, 100mg of feces were mixed in 500pl PBS containing 0.1% Tween 20 and protease / phosphatase inhibitor (Thermo Scientific, 78430). The mixture is vortex for 15 min to get homogenous fecal suspension, and subsequently centrifuged at 4,200 rpm for 10 min at 4°C. Protein concentration in the supernatant is measured by BCA assay protocol as per manufacturer protocol (Thermo Scientific, 23225).
[0087] Histology
[0088] Tissues (Liver, adipose tissues, and jejunum of small intestine) were fixed in 10% formalin for 24-48 h at 4°C, dehydrated, embedded into paraffin and sectioned (5pm) for H&E staining. Adipocyte size quantification was performed on H& E-stained sections of eWAT and ingWAT pads, using AdipoSoft software. 80 to 100 adipocytes per fat pad section and four sections per mouse were analyzed. Alcian blue staining protocol was used to stain goblet cells. Quantification of villi length, and crypt depth was performed using Fiji Imaged software measuring 25 villi and 40 crypts per mice24. Similarly, 20 villi and 60 crypts were used to quantify goblet cell count per villi and crypt respectively.
[0089] For oil red O staining, jejunum sections were fixed in 10% formalin for 24-48 h at 4 °C, cryopreserved with 30% sucrose solution, and embedded in OCT compound (Sakura, 4583). 10pm was used to stain with Oil red O solution (Sigma-Adrich, 01391).
[0090] Immunofluorescence
[0091] Whole-mount Jejunum IF staining protocol was adapted from Bernier-Latmani and Petrova, 2016 with modifications20. Briefly, Jejunum was cut into 1cm sections and fixed in 10% formalin for 24-48 h at 4°C, followed by overnight incubation with 30% sucrose solution. Jejunum tissue sections was blocked in 2% BSA blocking buffer containing 3% horse serum in 0.3% Triton X-100 and 1 % Tween20, for 2h at 4°C, and subsequently incubated with Rat anti-LYVE1 antibody (Thermo Scientific, 14-0443-82), overnight at 4°C. Jejunum tissue sections were washed in 0.3% Triton X-100 in PBS for 2h at 4°C with buffer changed every 30 min, followed by Goat anti-rat secondary antibody, Alexa Fluor 647 (Thermo Scientific, A-21247) overnight incubation at 4°C. Jejunum tissue sections were then thoroughly washed for 100 min with buffer changes every 10 min, then fixed in 10% formalin for24h. The jejunum tissue sections were cut into strips containing2-3 villi wide and mounted onto slides. Images were taken by confocal imaging (Zeiss LSM710).20 lacteals per mice were quantified using Fiji ImageJ software24.
[0092] RNAscope ISH Analysis
[0093] RNAscrope assay was performed using according to manufacturer’s protocol. Briefly, Jejunum sections were fixed in 10% formalin for 24-48 h at 4°C, dehydrated, embedded into paraffin and sectioned at 5 m thickness, and air-dried at room temperature overnight. Slides were treated and detected by fluorescence staining using Gpr75 probe (Advanced Cell Diagnostics, 318281) and RNAscope Multiplex Fluorescent Reagent Kit v2 (Advanced Cell Diagnostics, 323270). Negative control probe targeting DapB gene, and positive control probe targeting Polr2a gene was performed for each RNAscope ISH experiment. Images were taken by confocal imaging (Olympus FV3000).
[0094] Microbiota Profiling
[0095] Bacterial genomic DNA was extracted from feces of mice and 30ng of purified DNA was used for PCR amplification. Sequencing was performed with BGI’s proprietary DNBSEQ™ sequencing technology platforms.
[0096] Single-nucleus RNAseq analysis
[0097] The snRNA-seq data were obtained from the previous published study12and processed using Seurat27. Given the low and sparse expression of GPR75 in the human intestine, nuclei expressing ≥0.5 UMI count for GPR75 gene were identified as GPR75+ cells. The violin plots were generated using the Seurat package and ggplot2.
[0098] RNAseq and data analysis
[0099] For the RNA-seq assay, total mRNA was isolated from mouse jejunum samples using Trizol (Invitrogen, 15596018). The extracted total RNA was quantified using a Nanodrop 2000 spectrophotometer (Thermo Fisher) and assessed for quality using a Bioanalyzer. cDNA library preparation and mRNA sequencing were performed by Novogene, utilizing the state-of-the-art Illumina NovaSeq platforms and a paired-end 150 bp sequencing strategy.
[0100] For data analysis, the raw reads were initially processed with FastQC and Cutadapt to eliminate adapters, over-represented sequences, and low-quality sequences.Subsequently, the alignment of the reads was conducted using the HISAT2 software. SAMtools was utilized for sorting and converting the mapped reads to the BAM format. Following that, reads per kilobase per million (RPKM) values were calculated for each gene, and differentially expressed genes (DEGs) were identified using DESeq2, considering those with a fold change of more than 0.5 and a p value of less than 0.01. To further explore the biological implications of the DEGs, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) and Reactome enrichment analysis was carried out employing the clusterProfiler package. Gene sets with a P value below 0.05 were considered statistically significant.
[0101] Quantification and statistical analysis
[0102] Statistical analyses were performed using Prism (Graphad). No statistical methods were used to predetermine sample size. Values are presented as means + SD or mean + SEM, as indicated in figure legends. Statistical significance of differences was determined by unpaired, two-tailed student’s t test (two groups), with p values < 0.05 representing statistically significant. For indirect calorimetry, analysis is performed by CalR programme (https: / / calrapp.org / ).
[0103] To determine whether this phenotype could be attributed to a specific tissue, the inventors generated multiple tissue-specific knockout models targeting hepatocytes (Alb-Cre), intestinal epithelium (Vil-Cre), endothelial / hematopoietic lineages (77e2-Cre), and AgRP neurons (AgRP-Cre). Surprisingly, deletion of Gpr75 in hepatocytes, enterocytes, or endothelial cells failed to alter body weight gain under HFD conditions. Although AgRP-Cre-mediated deletion produced a modest reduction in male body weight gain (-10% after 12 weeks of HFD), this effect was substantially smaller than the -45% reduction observed in global knockout mice.
[0104] Result
[0105] GPR75 promotes obesity and associated metabolic syndromes
[0106] To elucidate the physiological and molecular function of GPR75 with respect to systemic energy homeostasis, we employed CRISPR / Cas9 system to generate whole-body knockout (Gpr75- / -) mouse model (Figure 1A and 1B). The deletion of Gpr75 was confirmed by measuring mRNA levels across multiple tissues (Figure S1C). Gpr75- / -mice were viable, fertile and normal in appearance without noticeable developmental defects. Mating between Gpr75+ / -mice produced offspring in the expected genotype distribution ratio of 1:2:1.
[0107] The inventors next measured the body weight of male and female Gpr75- / -mice and their control littermates (Gpr75+ / +) fed a normal chow diet. Male and female Gpr75- / -mice show similar body weight as Gpr75+ / +littermates upon weaning (Figure 1 D and 1 E). Of note, male Gpr75- / -mice exhibit a reduced body weight starting at five weeks of age compared to their control littermates (Figure 1D). This lean phenotype persisted into adulthood, stabilizing at a weight difference of approximately 10-12% (Figure 1D). Consistently, chow-fed GPR75-deficient mice exhibited significantly reduced weights of inguinal (iWAT) and epididymal (eWAT) adipose tissue, along with a trend of reduced liver weight, compared to their wild-type controls (Figure 1F). Furthermore, although significant body weight difference was not observed in female mice fed chow, weight of eWAT in GPR75-deficient mice were significantly less than those in wild-type littermates (Figure 1E and 1G).
[0108] Once start HFD (60% Kcal from fat) feeding, the body weight of male Gpr75+ / +and Gpr75- / -littermates began to diverge rapidly while female mice exhibited similar body weights during the first seven weeks of HFD feeding (Figure 2A and 2D). And after HFD feeding for 16 weeks, male Gpr75- / -mice display 29% less body weight compared to Gpr75+ / +mice (33.4+1.4g vs 46.8+5.0g) (Figure 2A). Furthermore, weights of liver, eWAT, ingWAT and BAT were profoundly reduced in male Gpr75- / -mice by 34%, 64%, 66%, and 43%, respectively, compared to control littermates (Figure 2B and 2C). The inventors further performed histological analysis showing significantly smaller adipocytes in both eWAT and iWAT from GPR75-deficient mice compared to control littermates (Figure 2G and 2H). Moreover, there is substantially reduced fat accumulation in iBAT from Gpr75- / -mice compared to control littermates (Figure 2G). Similarly, female GPR75-deficient mice showed 19% less body weight than Gpr75+ / +littermates after HFD feeding for 16 weeks (Figure 2D), with significantly reduced eWAT and ingWAT weight, but not liver and BAT, by 57% and 44%, respectively, upon GPR75 depletion. (Figure 2E and 2F).
[0109] The inventors next examined whether GPR75 deficiency protect against obesity-associated metabolic complications. Plasma triglyceride (TG) and total cholesterol (TC) levels were significantly reduced in Gpr75- / -mice compared to Gpr75+ / +littermates fed HFD (Figure 2I and 2J, Figure 1H and 11). Of note, GPR75 depletion did not affect plasma free fatty acid (FFA) levels under either chow or HFD feeding at any time measured (Figure 2K). Female GPR75-deficient mice did not show changes in plasma TC and FFA levels but showed a trend toward reduced plasma TG levels compared control mice under HFD feeding for 18 weeks (Figure 1J-1 L). In addition, overnight fasting glucose levels were similar between Gpr75+ / +and Gpr75- / -mice (Figure 1M and 1N).
[0110] Consistent with previous studies4, 7, depletion of GPR75 reduced liver TG contents by 58% and 47%, respectively, in male and female mice compared to their control littermates upon HFD feeding (Figure 2L and 2M). Liver cholesterol levels were significantly reduced in female, but not male, mice upon GPR75 depletion (Figure 2N). However, plasma ALT levels were only found to be significantly reduced in male, but not in female, knockout mice compared to control littermates (Figure 20). Collectively, these data suggest that depletion of GPR75 protects against diet-induced obesity and excessive fat accumulation in the liver.
[0111] Gpr75 knockout mice display unchanged food intake, reduced energy expenditure, and an increased respiratory exchange rate
[0112] The protective effect against HFD-induced fat accumulation in adipose tissue and liver is drastic upon GPR75 depletion. However, there is still debate about whether GPR75 regulates energy balance by modulating food intake or systemic energy expenditure4, 5, 6. To address this question, The inventors employed indirect calorimetry to evaluate the energy balance and substrate utilization in Gpr75+ / +' and Gpr75- / -littermates (10 weeks old) fed chow or HFD for 2 weeks. At this stage, their body weights just began to diverge rapidly, making it more likely to uncover the causal mechanism rather than adaptive effects (Figure 3A).
[0113] As a surprise, the inventors observed no differences in food intake under both chow and HFD feeding (Figure 3B-3E), despite GPR75 is highly expressed across the brain4, 7. Instead, the inventors observed a significant reduction in both daytime and nighttime energy expenditure in the knockout mice compared to wild-type littermates under chow, with a trend toward reduced energy expenditure under HFD feeding (Figure 3F-3I). Consistently, the body temperature of GPR75-deficient mice was significantly lower than control littermates (Figure 4A). Importantly, the respiratory exchange rate (RER) was significantly increased in Gpr75- / -mice (Figure 3J-3M and Figure 4B-4I), indicating a preference for utilizing carbohydrate over fats as energy source compared to Gpr75+ / +mice.
[0114] Additionally, while ambulatory activity and locomotor activity were not affected by GPR75 depletion in chow-fed mice, these activities were increased at nighttime in HFD-fed knockout mice (Figure 4J-4Q). Interestingly, we also found that Gpr75- / -mice consumed significantly more water than their control littermates at nighttime under both chow and HFD feeding conditions (Figure 4R-4U). Taken together, given that GPR75-deficient mice exhibited unchanged food intake, reduced energy expenditure, and increased RER, we hypothesized thatthe lean phenotype of GPR75 knockout mice is likely caused by attenuated dietary fat absorption in the gastrointestinal (Gl) tract.
[0115] Depletion of GPR75 results in significantly attenuated dietary fat absorption in the intestine
[0116] To test the hypothesis, the inventors next examined intestinal absorption of dietary fat by conducting a lipid tolerance test, in which an olive oil bolus was administered to mice via oral gavage, followed by measuring plasma TG levels over the course of two hours (Figure 5A). In 7-week-old chow-fed male mice, plasma TG increased at a similar rate between Gpr75+ / +and Gpr75- / -mice after olive oil gavage (Figure 6A). It’s well established that 10%-12% of intestinal TG output after a meal is derived from lipid stores accumulated from previous dietary fat intake9. These stored lipids are retained in the intestine within intracellular compartment, such as enterocytes, or extracellular compartment, such as the lamina propria and lacteals of the mesenteric lymphatic system, and are released in response to a second meal or other stimulatory factors10. To distinguish between stored lipids and newly absorbed fatty acids from olive oil bolus, the inventors added BODIPY-labelled fatty acid (BODIPY™ 500 / 510 C1, C12 (4,4-Difluoro-5-Methyl-4-Bora-3a,4a-Diaza-s-lndacene-3-Dodecanoic Acid) to the olive oil for gavage, allowing the inventors to directly quantify intestinal fatty acids absorption by measuring the BODIPY intensity in the plasma. Consistently, there was no difference in plasma BODIPY signals in the young male mice between with and without GPR75 (Figure 6B). When the chow-fed mice were older (12 weeks old), the inventors observed a trend of reduction in both blood TG and BODIPY levels in GPR75-deficient mice compared to control littermates (Figure 6C-6E).
[0117] After HFD feeding, the inventors found that Gpr75- / -mice displayed a substantially attenuated increase of plasma TG levels compared to control littermates over the two-hour time course following olive oil gavage (Figure 5B). Furthermore, plasma BODIPY measurements revealed significantly reduced plasma BODIPY intensities in Gpr75- / -mice two hours post-gavage, suggesting that the absorption of luminal free fatty acids was impaired upon GPR75 depletion (Figure 5C). Consistent with the reduced intestinal chylomicron-TG output, western blot analysis showed significantly reduced plasma ApoB48, but not ApoblOO, in Gpr75- / -mice compared to Gpr75+ / +littermates two hours after olive oil gavage (Figure 5D-5F). Of note, the inventors also conducted lipid tolerance test at early time point of HFD feeding (4 weeks), and GPR75 depletion consistently led to an attenuation of intestinal chylomicron-TG output compared to wild-type control littermates (Figure 6F). The reduced plasma TG and BODIPY levels in the lipid toleranceassay might be attributed to increased peripheral LPL activities due to absence of GPR75. To explore this possibility, the inventors measured post-heparin peripheral LPL activities and found no significant difference between GPR75-deficient mice and control littermates (Figure 6G). Taken together, these data suggest that GPR75 is likely to promote dietary fat absorption and chylomicron output in the intestine.
[0118] Depletion of GPR75 results in increased fecal lipid excretion
[0119] Given the unaffected food intake and reduced fat absorption upon GPR75 depletion, the inventors next investigated whether fecal lipid excretion was increased in Gpr75- / -mice compared to Gpr75+ / +littermates, the inventors collected feces every 24 hours for three consecutive days from individually housed mouse after four weeks of HFD feeding, a stage where fat mass expands rapidly. The data collected from two independent cohorts showed that total number and weight of daily expelled feces were significantly increased by 26% and 32%, respectively, in GPR75-deficient mice compared to control littermates (Figure 5G-5I). Water content in the feces did not appear to be affected, as the dried feces weight was significantly increased by 29% upon GPR75 depletion (Figure 6H). Further characterization of the collected feces revealed that the width and length of individual feces were similar between the two groups, indicating sufficient transit and processing along the gastrointestinal tract (Figure 6I).
[0120] Next, the inventors measured fecal lipid (TG, TC, and FFA) contents and found that relative lipid content (mg lipid / g feces) remains similar between Gpr75+ / +and Gpr75- / -mice (Figure 6J-6L). However, absolute excreted TG, TC, and FFA amount every 24 hours (mg lipid / day) were significantly higher in mice lacking GPR75 compared to their control littermates (Figure 5J-5L). Additionally, no differences in TG: FFA ratio was observed between Gpr75+ / +and Gpr75- / -mice, suggesting that the hydrolysis of dietary TG via pancreatic lipase was not significantly affected (Figure 6M). Of note, the inventors assessed protein / peptide levels in the feces and found that absolute excreted protein / peptide levels every 24 hours (mg / day) were significantly higher in mice lacking GPR75 compared to their control littermates, while the relative content (mg / g feces) remains similar (Figure 5M and Figure 6N). These data suggest that GPR75 deficiency might result in a systemic defect in intestinal lipid and protein absorption, which likely contributes to reduced whole-body energy expenditure and an increased utilization of carbohydrates as an energy source.
[0121] Given the substantially increased number of stools expelled per mouse during the 24 h of collection, the inventors next asked if the Gl transit time is accelerated upon GPR75 deficiency. To measure whole Gl transit, the inventors gavaged mice with carmine red, a nonabsorbable red dye with no nutritional value, after which was recorded the time for the first appearance of feces with red color. The inventors observed no significant difference in whole Gl transit time between GPR75-deficient mice and control littermates, suggesting that GPR75 does not play a role in regulating Gl motility (Figure 60). Overall, the major mechanism responsible for reduced fat mass and body weight in Gpr75- / -mice fed HFD is likely due to attenuated dietary lipids absorption along with increased lipid fecal excretion.
[0122] Depletion of GPR75 leads to shortened intestine length
[0123] To interrogate if the differences in lipid absorption is caused by impaired structure of intestine, the inventors performed histological analysis of intestine from mice under HFD feeding for 4 weeks. H& E and alcian blue staining revealed comparable villi length, crypt depth, and goblet cell numbers per villi between Gpr75+ / +mice and control littermates (Figure 6R-6V). Lacteal length also appears to be comparable between Gpr75- / -and Gpr75+ / +mice fed HFD (Figure 6P and 6Q).
[0124] Surprisingly, the total length of intestine, but not colon, was significantly reduced in Gpr75- / -mice compared to Gpr75+ / +littermates fed with HFD (Figure 5N-5P). Overall, these data suggest that while depletion of GPR75 did not alter villus structure, it did result in a reduction in intestine length. This reduction might contribute to the lean phenotype of GPR75-deficient mice or could be secondary to decreased body weight, as intestine length in humans is correlated with body weight11.
[0125] Single-cell RNA-Seq and histochemical profiling of GPR75 expression in the intestine
[0126] Given the Gl tract phenotype, the inventors next profiled GPR75 mRNA expression in the intestine in both humans and mice. In addition to the brain where GPR75 expression is widely distributed across various regions, its expression is detected in the intestine4, 7. The inventors first interrogated where GPR75 is expressed within intestine by employing a single-cell RNA sequencing (RNA-seq) dataset that consists of human intestine (Duodenum, jejunum, and ileum) and colon12. Among 160371 intestine cells and 119740 colon cells analyzed, GPR75 was detected in 0.063% and 0.115%, respectively, of these cells in the dataset (Figure 7A). Gpr75expression in the intestine and colon is heterogeneous, across a variety of regions and cell types including enterocytes, immature enterocytes, enteroendocrine cells, goblet cells, immune cells, stem cells, Paneth cells, transit amplifying cells (TA), myofibroblasts, endothelial cells, etc. (Figure 7B-7D, Figure 8A).
[0127] Due to great limitations of single-cell RNA-Seq in profiling mRNAs of low-expression GPCRs, the inventors next performed in situ hybridization (RNAScope) to map Gpr75 mRNA expression within the intestine. In agreement with single cell RNA-Seq data, the inventors found that GPR75 is widely distributed throughout the mucosa, submucosa, and muscularis externa, with the highest expression observed in epithelium, villus crypt, and laminar propria (Figure 7E). Taken together, these profiling suggest that Gpr75 is heterogeneously expressed and widely distributed in the intestine.
[0128] Transcriptom ic profiling of jejunum upon GPR75 depletion
[0129] To further explore the mechanism of how GPR75 regulates intestinal chylomicron output and fecal lipid excretion, the inventors performed transcriptome analysis of jejunum from mice fed HFD for 4 weeks. In total 455 differentially expressed genes (217 upregulated vs 238 downregulated) were uncovered upon depletion of GPR75 (Figure 7F). Unbiased gene set enrichment analysis (GSEA) by using three different databases, namely KEGG pathway gene sets, GO gene sets, and reactome pathway gene sets, revealed that GPR75 deficiency led to upregulation of pathways related to mucosa immune response and defense response to bacterium (Figure 7G, Figure 8B- 8E). In addition, cell-cell junction assembly, regulation of glucose transmembrane transport, ERK1 and ERK2 cascade, and potassium channel complex were significantly upregulated in intestine of GPR75-deficient mice compared to control littermates (Figure 7G, Figure 8B- 8E). In contrast, pathways related to cell cycle, triglyceride metabolic process, proteinogenic amino acid biosynthetic process, peroxisome, and fatty acid catabolic process were among the top downregulated pathways in the absence of GPR75 (Figure 7G, Figure 8B- 8E). To interrogate if the unregulated immune response is associated with impaired intestinal mucosa barrier integrity upon depletion of GPR75, the inventors performed assay to examine intestine permeability by oral gavage of FITC-dextran in HFD-fed mice. It was found that GPR75-mice exhibited significantly reduced intestinal permeability compared to control mice after 8 weeks of HFD feeding (Figure 8F).
[0130] GPR75-deficient mice exhibit a significant change in microbiome composition51
[0131] Given the Gl tract phenotypes observed in GPR75-deficient mice, the inventors next asked whether these changes also led to alterations in microbiome composition. 16S rRNA gene sequencing analysis of fecal samples from mice fed a HFD for 4 weeks revealed a significant reduction in Actinobacteria and an increase in Bacteroidetes in GPR75-deficient mice compared to control mice (Figure 9A- 9C, Figure 10). Additionally, GPR75 depletion showed a trend toward reduced Firmicutes, the most abundant phylum in the gut microbiome, compared to control littermates (Figure 9A-9C). In both humans and mice, Bacteroidetes is negatively correlated with obesity and fat mass, while Firmicutes is positively correlated with these traits. Studies have demonstrated that microbiota transplants from western diet-induced obese mice to lean germ-free recipients resulted in substantially increased fat deposition compared to transplants from chow-fed lean donors13 14. This effect is attributed to enhanced fermentation and an increased capacity for energy harvest in the microbiome of obese mice, likely driven by the increased abundancy of Firmicutes13, 14. Therefore, the observed microbial shift in GPR75-deficient mice is consistent with reduced energy harvest capacity and may represent either a contributing factor or a downstream adaptation to impaired dietary lipid assimilation.
[0132] Tissue-specific deletion of Gpr75 does not phenocopy the global knockout phenotype
[0133] While global Gpr75 deletion robustly protects against diet-induced obesity and is associated with impaired dietary lipid assimilation and altered gut microbiota, these findings do not establish whether the phenotype arises from GPR75 signaling within a specific tissue or from coordinated inter-organ mechanisms. Given the prominent gastrointestinal alterations observed in GPR75-deficient mice, the inventors first asked whether deletion of Gpr75 in intestinal cell types directly involved in nutrient absorption and chylomicron production could recapitulate the global phenotype.
[0134] Enterocytes are responsible for dietary lipid uptake and packaging into chylomicrons, while lacteal endothelial cells facilitate chylomicron transport into the circulation. To test whether impaired lipid assimilation resulted from cell-autonomous effects in these compartments, the inventors generated intestinal epithelial-specific (Vil-Cre) (Figure 11 A) and endothelial / hematopoietic-specific (Tie2-Cre) (Figure 12A) Gpr75 knockout mice. However, deletion of Gpr75 in either enterocytes (Figure 11 B-11E) or endothelial lineages (Figure 12B-12E) did not alter body weight gain under high-fat diet feeding, indicating that loss of GPR75 in theseindividual intestinal compartments is insufficient to reproduce the lean phenotype observed in global knockout mice.
[0135] Because GPR75-deficient mice exhibit marked protection against hepatic steatosis, and hepatocytes play a central role in systemic lipid handling, the inventors next generated hepatocyte-specific knockout mice using Alb-Cre (Figure 13A). Despite efficient deletion, Alb-Cre-mediated GPR75 deficiency did not affect body weight gain (Figure 13B and 13D), liver weight or adipose depot mass (Figure 13C and 13E), nor hepatic triglyceride accumulation (Figure 13F) in either male or female mice during high-fat feeding, suggesting that hepatocyte-autonomous GPR75 signaling is not the primary driver of the systemic metabolic phenotype.
[0136] Given the high expression of GPR75 in AgRP neurons and the established role of these neurons in regulating appetite and energy balance, the inventors further generated AgRP-Cre-mediated neuronal knockout mice (Figure 11F). In contrast to the other tissue-specific models, AgRP-Cre deletion resulted in a modest reduction in male body weight gain (~10% after 12 weeks of HFD) (Figure 11G and 11 H). However, this effect was substantially smaller than the ~45% reduction observed in global knockout animals, indicating that deletion of Gpr75 in AgRP neurons alone cannot fully account for the robust protection conferred by systemic deficiency. Collectively, these findings demonstrate that loss of GPR75 in any single tested tissue fails to phenocopy the global knockout, supporting a model in which GPR75 regulates diet-induced obesity through coordinated, multi-organ mechanisms rather than a dominant tissue-autonomous effect.
[0137] Discussion
[0138] Many lines of evidence, including human genetic association studies and research in animal models, have established GPR75 as a key regulator of diet-induced obesity2'4'5 6 7. However, the mechanism underlying the lean phenotype upon GPR75 inhibition remains largely unknown. In this study, the inventors generated global Gpr75 knockout mice using the CRISPR / Cas9 system and found that GPR75-deficient mice are protected against diet-induced obesity and excessive fat accumulation in the liver.
[0139] Interestingly, despite these protective effects, food intake remained unchanged in GPR75-deficient mice under both chow and high-fat diet (HFD) feeding conditions, even as body weight difference began to diverge rapidly. However, water intake was significantly increasedcompared to control littermates. Contrary to the expectation of increased energy expenditure accounting for the reduced fat mass, whole-body energy expenditure was notably decreased in GPR75-deficient mice compared to control littermates, regardless of diet. Consistently, body temperature of GPR75-deficient mice was significantly lower than control mice upon fasting. In line with reduced energy expenditure, the respiratory exchange ratio (RER) was significantly elevated in GPR75-deficient mice, indicating a shift towards carbohydrate utilization over fat as primary energy source. Further investigation revealed that this increased in RER was due to restricted fat availability, a result of impaired fat absorption and reduced chylomicron output in the intestine upon GPR75 depletion. Supporting this, absolute fecal TG / FFA excretion (mg lipid I day) was markedly increased in knockout mice compared to control littermates. This study thus uncovers that the protective effect against diet-induced obesity upon GPR75 inhibition is at least partially mediated by reduced lipid absorption in the intestine when the mice were fed with HFD.
[0140] Where does GPR75 control energy balance: brain, Gl tract, or both?
[0141] GPR75 is most highly expressed in the brain in both humans and mice, with widespread distribution across various brain regions4. This expression pattern in the brain differs from other well-known appetite-regulating genes, such as Agrp and Mc4r, which are more regionally localized15’10. The widespread distribution of GPR75 in the brain suggests that GPR75 may regulate energy balance through integrated neural circuitry rather than a single defined hypothalamic node.
[0142] Recent work using Nestin-Cre-mediated neuronal deletion demonstrated that brain-specific loss of Gpr75 is sufficient to protect against HFD-induced obesity, primarily through reduced food intake and modest increases in energy expenditure8. However, these neuronal knockout mice also exhibited a marked reduction in lean mass and depot-specific alterations in adipose tissue during prolonged high-fat feeding, characterized by unchanged subcutaneous fat mass but significantly increased visceral fat mass, with largely preserved adipocyte size8. These body composition changes differ substantially from those observed in global GPR75-deficient mice, which display robust reductions in fat mass with preserved lean mass and decreased adipocyte size. Thus, while broad neuronal GPR75 signaling clearly contributes to body weight regulation, neuronal deletion alone does not fully recapitulate the systemic metabolic phenotype of global deficiency.
[0143] To further dissect the neuronal contribution, the inventors selectively deleted Gpr75 in AgRP neurons, a key hypothalamic population controlling appetite and energy balance17. AgRP-Cre-mediated deletion produced only a modest reduction in male body weight gain (~10% after 12 weeks of HFD), markedly smaller than the ~45% reduction observed in global knockout mice. These findings suggest that although AgRP neurons may participate in GPR75-mediated energy regulation, they are unlikely to represent the dominant site responsible for the robust antiobesity phenotype of global GPR75 deficiency. Instead, multiple neuronal populations- or coordinated interactions between neural and peripheral tissues- are likely required.
[0144] In addition to the brain, GPR75 is expressed in other tissues, including intestine, white adipose tissue, and kidney, although at much lower levels4. Because the data demonstrate that reduced fat mass in global GPR75-deficient mice is associated with impaired intestinal lipid absorption and diminished chylomicron output, the inventors hypothesized that GPR75 might directly regulate dietary lipid handling within the gut. In situ hybridization revealed broad expression of GPR75 across the intestinal epithelium, lamina propria, villi crypts, and muscularis externa, supporting the possibility of local intestinal regulation. However, genetic interrogation of specific intestinal compartments did not support a dominant tissue-autonomous role. Deletion of Gpr75 in enterocytes (Vil-Cre) or endothelial / hematopoietic lineages (Tie2-Cre) failed to alter body weight gain under HFD feeding. Similarly, hepatocyte-specific deletion (A / b-Cre) did not affect body weight gain or hepatic lipid accumulation. Taken together with the modest AgRP-Cre phenotype, these findings indicate that deletion of Gpr75 in any single tested tissue is insufficient to phenocopy the robust global knockout.
[0145] Collectively, the data support a model in which GPR75 regulates diet-induced obesity through coordinated multi-organ interactions rather than a dominant tissue-autonomous mechanism. One possibility is that GPR75 signaling in the brain modulates intestinal lipid absorption through brain-to-gut communication pathways. Emerging evidence supports the existence of brain-to-gut communications that controls intestinal fat absorption18. Although the gastrointestinal tract possesses intrinsic neural circuitry, central nervous system inputs critically regulate gut motility, mucosal secretion, and intestinal blood flow19'20. Thus, the impaired intestinal lipid assimilation observed in global GPR75-deficient mice may reflect integrated neuron-gut signaling rather than isolated epithelial dysfunction. Importantly, during rapid HFD-induced fat mass expansion, diminished intestinal fat absorption and increased fecal excretion, rather than reduced food intake, appear to be the dominant mechanisms underlying reduced adiposity in GPR75-deficient mice.
[0146] Causal mechanisms underlying reduced fat mass upon GPR75 inhibition: less food intake, more fecal excretion, or both?
[0147] Under a chow diet, GPR75-deficient mice exhibit significantly reduced body weight early in life, around 5 weeks old in our study. Previous study has shown that GPR75-deficinet mice consumed less food immediately post-weaning, when these mice were becoming thin. However, food intake reached to control mice levels in older adult GPR75-deficient mice after the thin phenotypes was established6. In agreement with this finding, the measurement in this study of food intake of 10-week-old mice under both chow and HFD feeding did not reveal any significant difference between knockout and control mice, suggesting that hypophagia likely contributes to reduced fat mass in the early life stages of GPR75-deficient mice. Indeed, the body weight difference (approximately 9-10%) between GPR75-deficient mice and control littermates remains relatively stable from 7 to 15 weeks of age under chow feeding, which explains why food intake difference was no longer detectable in adult mice. However, given the substantial fat mass expansion during HFD feeding (approximately 7-fold increase in absolute fat mass after 16-week HFD feeding) and the drastically increased body weight difference between GPR75-deficient and control mice-growing from 10% under chow to almost 30% after 16 weeks of HFD feeding- other mechanisms likely contribute to the lean phenotype significantly in addition to the initial reduction in food intake during early life.
[0148] The present data indicates that during the period of rapid fat mass accumulation under HFD feeding, there is no difference in food intake between GPR75-deficient and control mice. Instead, GPR75-deficient mice exhibit significantly diminished fat absorption and increased fecal excretion, which appear to be the primary mechanisms driving the lean phenotype during this phase of HFD-induced fat mass expansion.
[0149] GPR75 regulates Gl tract phenotypes
[0150] The present data demonstrated that reduced chylomicron output likely explains the lean phenotype, diminished energy expenditure, and increased RER in GPR75-deficient mice. Intestinal chylomicron output consists of several steps, including dietary fat absorption, chylomicron assembly in enterocytes, trafficking and exit from the enterocytes, transport across the lamina propria, entry into lacteals, and circulation in lymphatics and blood10, 21. A reduction in chylomicron output could result from dysregulation at any of these stages.
[0151] In line with reduced intestinal chylomicron output, daily absolute fecal TG, TC, and FFA excretion (mg / day) were substantially increased in GPR75-deficient mice compared to control littermates fed HFD. Important to note that this increase in daily fecal lipid excretion is due to a greater total fecal output (g feces / day), while relative fecal lipid levels (mg lipid / g feces) remained similar between GPR75-deficient mice and control littermates. In addition, daily fecal protein excretion was significantly higher in GPR75-deficient mice, suggesting that the impaired nutrient absorption extends beyond dietary fat when GPR75 is inhibited. Importantly, the unchanged relative fecal TG levels (mg TG / g feces) in GPR75-deficient mice contrast with findings from Orlistat (a pancreatic lipase inhibitor) treatment, where relative fecal TG levels increased approximately 10-fold compared to placebo22, 23. All these taken together suggest that GPR75 deficiency leads to a systemic defect in intestinal lipid and protein absorption, which likely contributes to reduced whole-body energy expenditure and an increased utilization of carbohydrates as an energy source.
[0152] The increased absolute fecal excretion (g feces / day) suggests a potential increase in gut motility. However, the inventors did not find a significant difference in total Gl transit time between GPR75-deficient mice and control littermates. Consistent with this, water content in the stools was not affected upon depletion of GPR75. Furthermore, the width and length of individual stools were similar between GPR75-deficient mice and control littermates. Notably, the inventors observed a significant decrease in intestine length in male GPR75-deficient mice fed HFD, suggesting that GPR75 and its downstream signaling may have intestinotrophic effects.
[0153] Of note, GSEA analysis revealed that expression of several defensins was upregulated and enriched in the pathway related to defensive response to bacterial. Since defensins are anti-microbial peptides primarily produced by Paneth cells in the crypts, it is possible that GPR75 may play a role in regulating defensin synthesis in these cells. Despite transcriptome analysis indicated an upregulation of pathways related to immune response and anti-bacterial response, GPR75-deficient mice exhibited a significant reduction in gut permeability compared to control littermates. Furthermore, fecal microbiome analysis demonstrated that the microbial composition in GPR75-deficient mice was associated with a lean phenotype: characterized by a reduction in Firmicutes and an increase in Bacteroidetes compared to control littermates.
[0154] In summary, the study provides evidence that global GPR75 deficiency protects against diet-induced obesity and hepatic steatosis, at least in part, by limiting dietary lipidassimilation under HFD feeding. Therefore, antagonists targeting GPR75 are likely to be an efficient approach to tackle obesity and related metabolic syndromes.
[0155] EXAMPLE 2 -Development of small molecule antagonists inhibiting GPR75
[0156] To develop small molecule antagonists inhibiting GPR75, the inventors prepared crude ligand solution and used it as tool agonist for the screening of antagonists (Figure 14). By employing a state-of-the-art p-arrestin recruitment assay (PathHunter, DiscoverX), the inventors screened 10k diverse compounds stored in EDDC (ASTAR). After subsequent counter-screening and cell toxicity screening, the inventors have identified 23 candidate antagonists for GPR75. Further functional validation of all 23 candidates revealed that ANTAG75-1,2,3,4 robustly suppressed GPR75 activation-stimulated p-arrestin recruitment (Figure 15 and Table 1).
[0157] Table 1:
[0158] EXAMPLE 3- Pharmacological inhibition of GPR75 reduces diet-induced weight gain and improves metabolic parameters in mice
[0159] To evaluate the therapeutic efficacy of pharmacological GPR75 inhibition in vivo, a study was conducted using the GPR75 antagonist ANTAG75-4 in a diet-induced obesity mouse model.
[0160] Male C57BL / 6J mice (7 weeks old) were divided into two groups (n=10 per group) and fed a high-fat diet (HFD). After 10 days of HFD feeding, mice received either vehicle or ANTAG75-4 at a dose of 5 mg / kg administered by intraperitoneal (i.p.) injection (Figure 16A). The dosing regimen comprised an initial period of administration every other day for 2 weeks, followed by a maintenance period of dosing every three days during continued HFD feeding (Figure 16A).
[0161] At endpoint, mice treated with ANTAG75-4 exhibited significantly reduced cumulative body weight gain compared to vehicle-treated controls (P < 0.01) (Figure 16B and 16C). Tissue weights at endpoint were significantly reduced in ANTAG75-4-treated mice compared to vehicle-treated controls, including liver weight (Figure 16D), epididymal white adipose tissue (eWAT) weight (Figure 16E), and inguinal white adipose tissue (iWAT) weight (Figure 16F) (P < 0.01 for each).
[0162] Plasma metabolic parameters were also significantly improved in ANTAG75-4-treated mice compared to vehicle-treated controls. Specifically, ANTAG75-4 treatment resulted in significantly reduced plasma C-reactive protein (CRP) levels (Figure 16G), reduced plasma alanine aminotransferase (ALT) levels (Figure 16H), reduced plasma aspartate aminotransferase (AST) levels (Figure 161), reduced plasma triglyceride (TG) levels (Figure 16J), and reduced plasma total cholesterol (TC) levels (Figure 16K) (P < 0.01 for each).
[0163] Data were presented as mean ± SD. Statistical significance was determined by unpaired two-tailed Student's t-test.
[0164] These results demonstrate that pharmacological inhibition of GPR75 by a small molecule antagonist is sufficient to reduce diet-induced weight gain and improve multiple metabolic parameters in a mammalian subject, consistent with the phenotypic outcomes observed in GPR75-deficient (Gpr757“) genetic knockout models. These data support the therapeutic utility of GPR75 antagonists for the treatment of obesity and related metabolic diseases, including but not limited to hepatic steatosis, dyslipidemia, and systemic inflammation.REFERENCES
[0165] All citations and / or references recited herein are hereby incorporated by reference in their entirety.
[0166] 1. Lobstein, T., Brinsden, H. & Neveux, M. World Obesity Atlas 2022; 2022.
[0167] 2. Akbari, P. etal. Sequencing of 640,000 exomes identifies GPR75 variants associated with protection from obesity. Science 373 (2021).
[0168] 3. Choi, J. et al. A whole-genome reference panel of 14,393 individuals for East Asian populations accelerates discovery of rare functional variants. Sci Adv 9, eadg6319 (2023).
[0169] 4. Leeson-Payne, A. et al. Loss of GPR75 protects against non-alcoholic fatty liver disease and body fat accumulation. Cell Metab 36, 1076-1087 e1074 (2024).
[0170] 5. Hossain, S. et al. Gpr75-deficient mice are protected from high-fat diet-induced obesity. Obesity (Silver Spring) 31, 1024-1037 (2023).
[0171] 6. Powell, D. R. eta / . Mice Lacking Gpr75 are Hypophagic and Thin. Diabetes Metab SyndrObes 15, 45-58 (2022).
[0172] 7. Jiang, Y., Xun, Y. & Zhang, Z. Central regulation of feeding and body weight by ciliary GPR75. J Clin Invest (2024).
[0173] 8. Sun, X. N. et al. Neuronal GPR75 deficiency protects against diet-induced obesity in a humanized mouse model. Sci Adv 12, eady7993 (2026).
[0174] 9. Chavez-Jauregui, R. N., Mattes, R D. & Parks, E. J. Dynamics of fat absorption and effect of sham feeding on postprandial lipema. Gastroenterology 139, 1538-1548 (2010).
[0175] 10. Xiao, C., Stahel, P. & Lewis, G. F. Regulation of Chylomicron Secretion: Focus on Post-Assembly Mechanisms. Cell Mol Gastroenterol Hepatol 7, 487-501 (2019).
[0176] 11. Hounnou, G., Destrieux, C., Desme, J., Bertrand, P. & Velut, S. Anatomical study of the length of the human intestine. Surg Radiol Anat 24, 290-294 (2002).
[0177] 12. Hickey, J. W. et al. Organization of the human intestine at single-cell resolution. Nature 619, 572-584 (2023).
[0178] 13. Turnbaugh, P. J., Backhed, F., Fulton, L. & Gordon, J. I. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 3, 213-223 (2008).
[0179] 14. Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R. & Gordon, J. I. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027-1031 (2006).
[0180] 15. Jais, A. & Bruning, J. C. Arcuate Nucleus-Dependent Regulation of Metabolism-Pathways to Obesity and Diabetes Mellitus. Endocr Rev 43, 314-328 (2022).
[0181] 16. Loos, R. J. F. & Yeo, G. S. H. The genetics of obesity: from discovery to biology. Nat Rev Genet 23, 120-133 (2022).
[0182] 17. Johansen, V. B. L, Petersen, J., Lund, J., Mathiesen, C. V., Fenselau, H. & Clemmensen, C. Brain control of energy homeostasis: Implications for anti-obesity pharmacotherapy. Cell 188, 4178-4212 (2025).
[0183] 18. Lyu, Q. etal. A brain-to-gut signal controls intestinal fat absorption. Nature (2024).
[0184] 19. Sanders, K. M., Koh, S. D., Ro, S. & Ward, S. M. Regulation of gastrointestinal motility-insights from smooth muscle biology. Nat Rev Gastroenterol Hepatol 9, 633-645 (2012).
[0185] 20. Browning, K. N. & Travagli, R. A. Central nervous system control of gastrointestinal motility and secretion and modulation of gastrointestinal functions. Compr Physiol 4, 1339-1368 (2014).
[0186] 21. Wit, M., Trujillo-Viera, J., Strohmeyer, A., Klingenspor, M., Hankir, M. & Sumara, G. When fat meets the gut-focus on intestinal lipid handling in metabolic health and disease. EMBO Mol Med 14, e14742 (2022).
[0187] 22. Hartmann, D., Hussain, Y., Guzelhan, C. & Odink, J. Effect on dietary fat absorption of orlistat, administered at different times relative to meal intake. Br J Clin Pharmacol 36, 266-270 (1993).
[0188] 23. Hussain, Y., Guzelhan, C., Odink, J., van der Beek, E. J. & Hartmann, D. Comparison of the inhibition of dietary fat absorption by full versus divided doses of orlistat. J Clin Pharmacol 34, 1121-1125 (1994).
[0189] 24. Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat Methods 9, 676-682 (2012).
[0190] 25. Folch, J., Lees, M. & Sloane Stanley, G. H. A simple method forthe isolation and purification of total lipides from animal tissues. J Biol Chem 226, 497-509 (1957).
[0191] 26. Bernier-Latmani, J. & Petrova, T. V. High-resolution 3D analysis of mouse small-intestinal stroma. Nat Protoc 11, 1617-1629 (2016).
[0192] 27. Stuart, T. et al. Comprehensive Integration of Single-Cell Data. Cell 177, 1888-1902 e1821 (2019).
Claims
1. CLAIMS1. A compound of formula I, formula II, formula III or formula IV, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof:X, Y, Z, and Q are independently C, S, O, or N;R1is a 3-6 membered monocyclic ring;R2is H or a halogen; andR3, R4, R5, and R6are independently H or Ci-C6alkyl, optionally the Ci-C6alkyl is substituted with one or more halogens.
2. The compound of claim 1, wherein the compound is an antagonist of the G protein-coupled receptor 75 (GPR75).
3. The compound of claim 1 or 2, wherein the compound exhibits an IC50 of less than 10 μM, 5 μM, 2 μM, or 1 μM for inhibition of GPR75.
4. The compound of any one of claims 1-3, wherein the compound selectively inhibits GPR75, preferably with at least 2-fold, at least 5-fold, at least 10-fold, at least 20-fold, at least 50-fold, or at least 100-fold greater potency for GPR75 relative to G protein-coupled receptor 146 (GPR 146).
5. A method of treating a metabolic disease in a subject, the method comprising administering a therapeutically effective amount of a compound of formula I, formula II, formula III or formula IV, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, to the subject in need thereof:(Formula I),(IV);wherein:X, Y, Z, and Q are independently C, S, O, or N;R1is a 3-6 membered monocyclic ring;R2is H or a halogen; andR3, R4, R5, and R6are independently H or Ci-C6alkyl, optionally the Ci-C6alkyl is substituted with one or more halogens.
6. The method of claim 5, wherein the metabolic disease is a G protein-coupled receptor 75 associated metabolic disease.
7. The method of claim 5 or 6, wherein the metabolic disease is obesity, Type 2 Diabetes (T2D), cardiovascular disease (CVD), Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) I Non-Alcoholic Fatty Liver Disease (NAFLD), or insulin resistance or a combination thereof.
8. A method of reducing intestinal fat absorption, increasing fecal lipid excretion, modulating gut microbiome composition, reducing intestinal permeability, improving gut barrier integrity and / or reducing chylomicron secretion in a subject, the method comprises administering a therapeutically effective amount of a compound of formula I, formula II, formula III or formula IV, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, to the subject in need thereof:formula (IV);wherein:X, Y, Z, and Q are independently C, S, O, or N;R1is a 3-6 membered monocyclic ring;R2is H or a halogen; andR3, R4, R5, and R6are independently H or Ci-C6alkyl, optionally the Ci-C6alkyl is substituted with one or more halogens.
9. The method of claim 8, wherein the compound inhibits or reduces the activity of G protein- coupled receptor 75.
10. The compound of any one of claims 1-4, or the method of any one of claims 5-9, wherein, in the compound of formula I, formula III or formula IV, X and Y are both N or both S.
11. The compound of any one of claims 1-4 and 10, or the method of any one of claims 5-9 and 10, wherein, in the compound of formula II, formula III or formula IV, Z and Q are both N.
12. The compound of any one of claims 1-4 and 10-11, or the method of any one of claims 5- 9 and 10-11, wherein, in the compound of formula I, R1is a C3-C6cycloalkyl.
13. The compound of any one of claims 1-4 and 10-12, or the method of any one of claims 5- 9 and 10-12, wherein, in the compound of formula I, formula III or formula IV, R2is Cl or F.
14. The compound of any one of claims 1-4 and 10-13, or the method of any one of claims 5- 9 and 10-13, wherein, in the compound of formula II or formula III, R3is a Ci or C2alkyl.
15. The compound of any one of claims 1-4 and 10-14, or the method of any one of claims 5- 9 and 10-14, wherein, in the compound of formula II or formula IV, R4and R5are both methyl groups, preferably, in the compound of formula II, R4and R5are both methyl groups further substituted with one or more halogens, more preferably, in the compound of formula II, R4and R5are both methyl groups further substituted with two F.
16. The compound of any one of claims 1-4 and 10-15, or the method of any one of claims 5- 9 and 10-15, wherein, in the compound of formula IV, both R3and R6are ethyl groups.
17. The compound of any one of claims 1-4 and 10-16, or the method of any one of claims 5- 9 and 10-16, wherein the compound of formula I, formula II, formula III or formula IV is:or a pharmaceutically acceptable salt, solvate, hydrate, or stereoisomer thereof.
18. The compound of any one of claims 1-4 and 10-17 for use in treating a metabolic disease in a subject in need thereof.
19. The compound of any one of claims 1-4 and 10-17 for use in reducing intestinal fat absorption, increasing fecal lipid excretion, modulating gut microbiome composition, reducing intestinal permeability, improving gut barrier integrity and / or reducing chylomicron secretion in a subject.
20. A method of treating a metabolic disease in a subject, the method comprising administering a therapeutically effective amount of:or a pharmaceutically acceptable salt, solvate, hydrate, or stereoisomer thereof, to the subject in need thereof.
